

Human Medicines Regulations 2012

Advisory Bodies

British Pharmacopoeia Commission

Annual Report 2024

Published July 2025



**Medicines and Healthcare products Regulatory
Agency**

**HUMAN MEDICINES REGULATIONS 2012
ADVISORY BODIES**

British Pharmacopoeia Commission

**ANNUAL REPORT
2024**

**Laid before Parliament pursuant to
Part 2, Regulation 12(4) of
the Human Medicines Regulations 2012**



© Crown copyright 2025

**Published by the Medicines and Healthcare
products Regulatory Agency**

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

ISBN 978-1-8384147-4-0

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

Table of Contents

Foreword by the Minister of State for Health	10
BRITISH PHARMACOPOEIA COMMISSION ANNUAL REPORT FOR 2024	12
Introduction	12
The membership	13
Code of practice	14
Meetings.....	15
Secretariat.....	15
Laboratory	15
Costs	16
Progress and publications.....	17
British Pharmacopoeia 2024.....	17
British Pharmacopoeia 2025.....	17
British Pharmacopoeia (Veterinary) 2025.....	19
British Approved Names 2022	20
Digital Publications.....	20
Prices and Availability	21
Future Publications	22
Other pharmacopoeial matters	23
Biological Medicines	23
Unlicensed Medicines	25
Herbal and Complementary Medicines.....	26

Nomenclature.....	26
Sustainability	27
Liaison with Other UK Organisations.....	28
Laboratory	29
BP Reference Materials	30
European Pharmacopoeia	30
International Liaison and Collaboration	33
Acknowledgements.....	35
APPENDIX I.....	37
BRITISH PHARMACOPOEIA COMMISSION PUBLICATIONS DURING 2024	37
APPENDIX II.....	39
Membership of the British Pharmacopoeia Commission	39
Membership of the Anti-Infective Medicines Expert Advisory Group (AIM EAG).....	43
Membership of the Biological and Biotechnological Products Expert Advisory Group (BIO EAG)	45
Membership of the Herbal and Complementary Medicines Expert Advisory Group (HCM EAG)	48
Membership of the Medicinal Chemicals Expert Advisory Group (MC1 EAG).....	52
Membership of the Medicinal Chemicals Expert Advisory Group (MC2 EAG).....	54

Membership of the Medicinal Chemicals Expert Advisory Group (MC3 EAG).....	57
Membership of the Pharmacy and Nomenclature Expert Advisory Group (PCN EAG).....	60
Membership of the Unlicensed Medicines Expert Advisory Group (ULM EAG).....	62
Membership of the Panel of Experts for Blood Products (BLP Panel).....	63
Membership of the Panel of Experts for Excipients (CX Panel).....	64
Membership of the Panel of Experts for Inorganic and General Chemicals (IGC Panel)	65
Membership of the Panel of Experts for Microbiology (MIC Panel)	66
Membership of the Panel of Experts for Radioactive Materials (RAD Panel)	67
Membership of the Panel of Experts for Veterinary Medicines (VET Panel)	68
Membership of the Panel of Experts for Veterinary Immunological Products (VIP Panel)	69
Membership of the Analytical Quality by Design Working Party (AQbD WP)	70
Membership of Advanced Therapy Medicinal Products Working Party (ATMP WP)	73

Membership of Alternative Approaches for
Documentary and Physical Standards for
Biotechnological Products Working Party (BIO-DPS
WP) 80

EUROPEAN PHARMACOPOEIA COMMISSION –
Members of the United Kingdom Delegation During
2024 81

DECLARATION OF INTERESTS..... 83

Foreword by the Minister of State for Health

It gives me great pleasure to present the annual report for 2024 of the Human Medicines Regulations Advisory Bodies: The British Pharmacopoeia Commission. This report includes a record of members' interests in the relevant industry as per the Conflicts of Interest Code of Practice.

On behalf of all Health Ministers, I would like to thank the Chairs and Members of the Commission and all those who contribute to their many Expert Advisory Groups, Panels of Experts and Working Parties whose professional expertise, commitment and hard work plays a vital role in ensuring that the medicinal products we take continue to meet the highest standards of safety, quality and efficacy.

Karin Smyth MP

BRITISH PHARMACOPOEIA COMMISSION

BRITISH PHARMACOPOEIA COMMISSION ANNUAL REPORT FOR 2024

Introduction

The British Pharmacopoeia Commission (BPC), appointed under Part 2 of the Human Medicines Regulations 2012 (the 2012 Regulations), is responsible under regulation 317 for preparing new editions of the British Pharmacopoeia (BP) and the British Pharmacopoeia (Veterinary) (BP Vet) and for keeping them up to date. It also provides advice to the United Kingdom (UK) delegation to the European Pharmacopoeia Commission (EPC), of which the UK is a member by virtue of its obligations under the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50). Under regulation 318 of the 2012 Regulations, the BPC also selects and devises names to be used at the head of monographs, which are subsequently published as British Approved Names (BAN).

It is of paramount importance that the medicines received by patients are safe, effective and of a suitable quality. The BP and BP(Vet) contribute significantly to the quality of medicines for human use and for animal

use by providing publicly available, legally enforceable standards which are part of the overall system for safeguarding the health of patients in the UK and beyond. The BP is used across the globe and referenced in the legislation of several countries.

The membership

A list of members of the BPC during 2024 is shown in this report.

The terms of office for two lay members of the BPC ended on 31st December 2023. Following a comprehensive review conducted in collaboration with the Department of Health and Social Care Appointments and Honours Team, seven new members, five technical experts and two lay members were successfully appointed for a four-year term starting on 3rd June 2024.

Additionally, the second terms of office for three members were set to conclude on 21st June 2024. As part of the re-appointment process, one member's term was extended by one year, while two members received a four-year extension, all effective from 22nd June 2024.

A list of members of the supporting Expert Advisory Groups (EAGs), Panels of Experts and Working Parties (WPs) for 2024 is given in Appendix II.

Code of practice

1. Members of the BPC are required to comply with the Medicines and Healthcare products Regulatory Agency (MHRA) Code of Practice on Identifying, Declaring and Managing Interests. This new Code of Practice was launched on 8th September 2022 and replaced the former BPC Code of Practice. Members of the EAGs, Panels of Experts and WPs are also required to comply with the new Code of Practice. Members of the BPC and its supporting EAGs, Panels of Experts and WPs are permitted to hold personal interests in the pharmaceutical industry, with the exception of the Chair of the BPC. This allowance ensures that the BPC and its supporting groups benefit from the practical insights and up-to-date knowledge that these technical members bring from their active roles in the industry. The Code of Practice link can be found here [Code of Practice for the British Pharmacopoeia Commission and other expert advisory committees](#).

Meetings

2. The BPC met three times during 2024. Twelve meetings of the EAGs, Panels of Experts and WPs were also held during the year, together with several meetings of the four sub-groups of the Working Party on Advanced Therapy Medicinal Products (ATMP WP).
3. Summary Minutes of the meetings of the BPC and its EAGs, Panels of Experts and WPs can be found on the BP website ([Meetings and minutes - British Pharmacopoeia](#)).

Secretariat

4. The BP Secretariat is based at 10 South Colonnade, Canary Wharf, London E14 4PU.

Laboratory

5. The Laboratory is based at the Laboratory of the Government Chemist (LGC) (Teddington) and is managed under a collaboration agreement with LGC.

Costs

6. For each meeting that they attend, members of the BPC are entitled to claim a taxable attendance fee of £325 (Chair's fee, £500). Members of the EAGs, Panels of Experts and WPs are entitled to claim a taxable attendance fee of £200 per meeting attended (Chair's fee, £325). Travel and subsistence costs are also payable within MHRA guidelines.

Progress and publications

British Pharmacopoeia 2024

7. Following publication of the BP 2024, three online updates were issued providing users with the texts of Supplements 11.3 to 11.5 of the 11th Edition of the European Pharmacopoeia.

British Pharmacopoeia 2025

8. The BP 2025 was published in August 2024. This new edition is available as a package containing the five volumes of the BP 2025, the one volume of the BP (Vet) 2025 and access to the electronic versions of both publications (online BP and offline download format).
9. This new edition contains over 4000 monographs for substances and articles used in the practice of medicine and almost 500 infrared reference spectra, together with the necessary appendices and supporting material. The effective date of the BP 2025 is 1st January 2025.

10. All monographs published within the 11th Edition of the European Pharmacopoeia, as amended by Supplements 11.1 to 11.7, are included either in this edition of the BP or, where appropriate, in the associated edition of the BP (Vet). Monographs of the European Pharmacopoeia are clearly distinguished from those of national origin by means of a chaplet of stars that appears alongside the monograph title. Where appropriate, statements of relevance to UK usage, such as Action and Use and the list of BP preparations, have been added to the European Pharmacopoeia monographs.
11. The BP 2025 contains 14 new monographs and texts of national origin which were not published in previous editions. A significant number of national monographs were amended in respect of technical or editorial content (105 in total) and the titles of 9 national monographs and one appendix name were amended in this edition.
12. Four new Appendices: Appendix XIV Q. Assay of Bet v 1 Allergen; Appendix XIV S. Monocyte-Activation Test for Vaccines Containing Inherently Pyrogenic Components; Appendix XVIID. Particle Size and Shape Determination by Image Analysis and Appendix XVII L. Particle Size Analysis by

Dynamic Light Scattering have been incorporated by means of this edition.

13. One new Supplementary Chapter was added by means of this edition, SC IV W. Comparability of Alternative Analytical Procedures.
14. Five national monographs for products no longer marketed were omitted from the BP 2025 following consultation. In accordance with Regulation 252(2)(c) of the 2012 Regulations, omitted monographs continue to remain in force.

British Pharmacopoeia (Veterinary) 2025

15. The BP (Vet) 2025 was published as a companion volume to the BP 2025 in August 2024. This new edition contains monographs, infrared reference spectra and a number of appendices relating to materials used solely in veterinary medicine. The effective date of the BP (Vet) 2025 is 1st January 2025.

16. The BP (Vet) 2025 contains two new monographs of national origin which were not published in previous editions.

British Approved Names 2022

17. BAN 2022 (Supplement No.3) was published in August 2024. This Supplement defines 24 new chemical and biological entities that are used in medicines in the UK. The majority of the new names are for active substances used in medicinal products that have not previously been marketed in the UK.
18. Following the successful development and release of the new format for the online BAN publication and as part of the BP's ongoing sustainability initiatives, the BAN and its supplements will no longer be published in a hard copy format.

Digital Publications

19. The BP 2025 publications can be accessed through the online version (pharmacopoeia.com) and the offline download edition. Both formats have been updated to include the European Pharmacopoeia

supplements 11.6 to 11.7 and will be updated in 2026 to include supplement 11.8.

20. The BP website has continued to be positively received by users. Several improvement features have been added to the BP 2025 online publication including a new accounts and dashboard for every user of the BP, the ability to provide feedback on every page, a live webchat feature and a new tool for users to sign up for updates as well as simpler processes for purchasing. Further improvements are being developed based on user feedback through extensive customer research.
21. Following the regular public consultation scheduled for new and revised monographs, four three-month consultation periods were held during 2024. This continued to provide users with the opportunity to contribute to the monograph development and revision process, helping to ensure that published monographs are relevant and robust.

Prices and Availability

22. Details of the prices and availability of the above-mentioned publications are shown in **Appendix I**.

23. In addition, users can purchase access to a maximum of three individual BP monographs, together with the necessary supporting information including the Introduction, General Notices, Appendices and Supplementary Chapters.

Future Publications

24. By the end of 2024 work was progressing on the preparation of the next editions of the BP and BP (Vet). These will be published during 2025 and will have an effective date of 1st January 2026.
25. A digital update to the BP 2025 was issued in October 2024, providing users with the text of the Supplement 11.6 of the 11th Edition of the European Pharmacopoeia which came into effect on 1st January 2025. A further update was issued in December providing users with the text of Supplement 11.7, which will come into effect on 1st April 2025. Supplement 11.8 will be available in advance of its implementation on 1st July 2025. These updates will only be available via the online BP and the offline download. The texts will subsequently be included in the BP 2026 publications as appropriate.

Other pharmacopoeial matters

Biological Medicines

26. While continuing to maintain quality standard monographs for biological products, the main focus during the year has been the continued development of non-mandatory guidance for the analysis of cell and gene therapy products.

27. The ATMP WP continued to develop non-mandatory guidance documents that support quality and innovation in these medicines. Guidance documents for “Characterisation of the capsid particle population in rAAV products” and “T cell and NK cell characterisation assays” were made freely available on the British Pharmacopoeia website www.pharmacopoeia.com/guidance/atmp in January and March 2024 respectively. The published guidance was developed and approved by the BP, as part of the MHRA, in partnership with experts from the cell and gene therapy community including representatives from industry, the NHS and academia.

28. In December, a draft guidance document was published for consultation on “Replication-competent virus assays” with a further guidance document expected to be published for consultation in early 2025 on “Validation protocols and reports for digital and quantitative polymerase chain reaction for vector copy number and genomic titre”. Two new groups have also been established to work to produce guidance for topic areas related to encapsidated DNA characterisation and capsid protein characterisation.
29. The importance of stakeholder contributions and systems-wide approaches is recognised, and the ATMP WP includes representatives from the NHS, academia, industry, and the UK Catapult network. In addition, a close working relationship between the MHRA and the Cell and Gene Therapy Catapult has been extended and continues to support the work and continued staff development in both organisations. The Working Party continues to focus on horizon scanning and identifying new topics and is working to produce further non-mandatory guidance documents for the ATMP community.

30. The BIO-DPS Working Party (Alternative Approaches for Documentary and Physical Standards for Biotechnological Products) has continued to explore the potential of performance and class-based standards for biotechnological products. The results from the international multi-laboratory monoclonal antibody analysis were used to assess the value of alternative standards with discussions held to re-establish concepts and outline future next step approaches for the study.

Unlicensed Medicines

31. Monographs that have been developed to cover unlicensed formulations are identified as such in the BP. These monographs provide legally enforceable standards for unlicensed formulations which may be widely used or are required for certain patient populations. The BP is also continuing to develop further guidance for prescribers, manufacturers and suppliers of unlicensed medicines which will be included in future publications.
32. A number of monographs for unlicensed formulations are being developed as part of a series of family monographs alongside those for licensed

products containing the same active ingredient. This initiative will make the most efficient use of Laboratory resources and will provide assurance that the methods for the unlicensed formulations are suitable.

Herbal and Complementary Medicines

33. Following public consultation on new extract monographs, monographs for Green Tea Extract and Decaffeinated Green Tea Extract were published in the BP 2025 edition and work is progressing on further extract monographs.

34. In parallel, work to maintain and update the existing monographs for herbal medicines which are still used and would benefit from modernisation continued, and revised monographs for Capsicum Tincture, Ispaghula Husk Granules, Podophyllum Resin and Compound Podophyllum Paint were published in the BP 2025.

Nomenclature

35. The BP continued to provide advice and comments to the World Health Organization (WHO) Committee on International Non-proprietary Names (INN). Recommended INN (rINN) for products licensed in the UK are formally adopted as BANs when they are first included in licensed medicines. UK Experts provided input into two INN Consultations during the year and contributed to the evaluation of INN requests and the development of WHO policies on drug nomenclature. Two rINN Lists (91 and 92) were published by WHO during the year.
36. The BP Secretariat is also responsible for advising the MHRA on the acceptability of proposed invented names for medicines in the UK. BP staff also continue to provide advice to manufacturers on the acceptability of invented names and remain the experts on the acceptability of invented names within the MHRA.

Sustainability

37. Since the publication of the first BP Sustainability Information Pack in March 2024, this has been downloaded by over 100 BP users. This pack aims to address environmental impacts associated with

quality control testing, primarily in laboratory settings, and includes several case studies from stakeholders to support the adoption of greener practices. Work is ongoing to update the Sustainability Information Pack in 2025.

38. Trials in the BP laboratory to reduce solvent usage during quality control testing through method adjustments were successful. These trials included solvent recirculation and avoiding solvent pre-mixing, demonstrating significant reductions in solvent usage without compromising test results.
39. Proposals to integrate sustainability into the monograph elaboration and revision process have been introduced, including scaling down column sizes and utilising method greenness calculators. A scaled method for Solifenacin Oral Suspension was published as an additional resource in the 2025 edition of the BP and further scaled methods will be introduced in future publications.

Liaison with Other UK Organisations

40. The BP and Veterinary Medicines Directorate (VMD), an executive agency of the Department for Environment, Food and Rural Affairs, continue to

collaborate closely on the development of monographs for veterinary medicines through representation from the VMD on Expert Advisory Groups.

41. The MHRA is a member of a Pharmaceuticals in the Environment (PiE) collaboration of UK regulators including the VMD, Environment Agency, Health and Safety Executive, and devolved nations equivalents. This group aims to address the prevalence of certain animal and human medicines in the water tables of the UK through monitoring and regulatory action. This is also pertinent to addressing anti-microbial resistance (AMR). The BP is supporting the MHRA Partnerships group in this task.

Laboratory

42. The Laboratory has continued to support the work of the BPC and the wider MHRA remit relating to public health throughout 2024.
43. During the year laboratory work on 37 new and revised BP monographs was undertaken for inclusion in future publications. The Laboratory also

provided data to support several regulatory investigations during the year.

BP Reference Materials

44. Eleven new BPCRS were established to support the BP and BP (Vet) publications, sixty-five were replaced and two hundred were re-tested to ascertain their continued stability.
45. All new BPCRS that were introduced into the BP 2025 and BP (Vet) 2025 were made available by July 2024 in advance of the publication in August 2024. Making the materials available as early as possible ensures that users are ready to comply with the new and revised monographs before they come into force.
46. The demand for these reference materials remained high throughout the year. A total of 38,786 vials were sold within the UK and to countries worldwide, representing an increase of approximately 7 % compared to the previous year.

European Pharmacopoeia

47. The fifth and sixth Supplements to the 11th Edition of the European Pharmacopoeia (Supplements 11.5 and 11.6) were published in January 2024 and July 2024 respectively. Supplement 11.5 came into effect on 1 July 2024 and Supplement 11.6 has come into effect on 1 January 2025. The seventh Supplement (11.7) was published in January 2025 and will come into effect on 1 April 2025. The text of these publications was included in the online BP in advance of their effective date and will be published in the next editions of the BP and BP (Vet) as appropriate.
48. The UK continued to play a highly active role in supporting the work of the EPC and its Groups of Experts and Working Parties, providing experts to groups that are most relevant to the UK market. Members of the UK delegation represented the BPC at meetings of the EPC, providing valuable input to the work of that Commission.
49. The Laboratory provides technical support for the work of the EPC, providing technical data to support the elaboration of new monographs and the revision of existing monographs.
50. A list of the current membership of the United Kingdom delegation, and the names of the UK

members of Groups of Experts and Working Parties during 2024, is included in Appendix II.

International Liaison and Collaboration

51. Liaison was maintained on a wide range of topics relating to pharmacopoeial matters and nomenclature with various international organisations and bodies including the World Health Organization (WHO) and the United States Pharmacopeia (USP).
52. In preparation for the fifteenth International Meeting of World Pharmacopoeias, to be hosted in New Delhi by the Indian Pharmacopoeia Commission (IPC), BP Secretariat staff have led a project to create a Terms of Reference document with the goal to improve governance and focus, and to support the India/US-led project on climate-friendly principles. Both projects have progressed to target, with the goal of all parties agreeing to text in the meeting scheduled for February 2025.
53. Throughout the year BP Secretariat staff provided feedback to WHO on draft monographs for the International Pharmacopoeia, which was greatly appreciated. Many of the standards included in the International Pharmacopoeia, and the policies employed, are consistent with those in the BP.
54. The BP attended the 58th WHO Expert Committee meeting on Specifications for Pharmaceutical

Preparations in October during which monographs and reference materials for the International Pharmacopoeia were discussed.

55. The BP hosted the Chief Scientific Officer and delegation from the United States Pharmacopoeia in London in October. Topics discussed included continuation of harmonisation of drug product monographs, ICH topics, biologics and the environmental footprint of pharmaceuticals as well as the International Meeting of World Pharmacopoeias projects (see 52 above)
56. BP staff attended the 78th and 79th WHO Consultations on INN in April and October. This regular INN committee discussed and agreed a significant number of names for new chemical and biological substances at both meetings.

Acknowledgements

57. The BPC wishes to express its gratitude to all EAG, Panel and WP members for the invaluable contribution they have made towards the continuing improvement of standards in the BP and to members of the United Kingdom delegation to the EPC and to UK members of its Groups of Experts and Working Parties who have unstintingly provided time, attention, and expertise to the work of that BPC. In particular, the BPC wishes to acknowledge the contribution of those members who have now retired from the EAGs, Panels of Experts and WPs of the BPC.
58. The BPC also wishes to record its immense gratitude to the staff of the BP and Laboratory Services Group of the MHRA. Significant input to the work of the BPC continued to be received from members of staff from the following Groups of the MHRA: Healthcare, Quality & Access; Scientific Research & Innovation; Communications and Engagement. Significant input has also been received from the BP and MHRA Laboratories, from the Department of Health and Social Care, from the Cell and Gene Therapy Catapult and from the Veterinary Medicines Directorate.

59. The BPC wishes to acknowledge the advice of the publishing team at The Stationery Office (TSO) in the production of the BP 2025, the BP (Vet) 2025 and Supplement No.3 to BAN 2022.

APPENDIX I

BRITISH PHARMACOPOEIA COMMISSION PUBLICATIONS DURING 2024

Publications may be purchased from TSO Customer Service Centre, or from the British Pharmacopoeia's pharmacopoeia.com website.

British Pharmacopoeia 2025 package

Consisting of: -

British Pharmacopoeia 2025

British Pharmacopoeia (Veterinary) 2025

Online Access (single-user licence, allowing access to three in-year electronic updates)

BP Download Edition (single-user licence)

(£1000 for a package consisting of print, online and download of the edition or £875 for each individually)

Individual BP Monograph (only supplied electronically)

(Price £200 for the first text, £150 each for the second and third texts)

British Approved Names

British Approved Names 2022: Supplement No.3
(including Supplements 1 to 3)

(Price £150, available online only)

APPENDIX II

Membership of the British Pharmacopoeia Commission

Post	Name and title	Affiliations
Chair	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Vice Chair	Mr Robert Lowe BPharm FRPharmS	Director of Pharmacy Quality Assurance Specialist Services, NHS East of England & Northamptonshire
Lay Member	Mrs Hayley Hall ¹ BA	Public representative on NIHR's Strategy and Engagement Board
Lay Member	Ms Claire Nicholson ² BA Dipl.-Betriebswirt MBA	Lay/consumer member on the Food Standards Agency Science Council

¹ Appointed 03/06/2024

² Appointed 03/06/2024

Member	Dr Emre Amirak³ BSc MBBS MRCS	Chief Medical Officer, Proveca Limited; Chief Medical Officer & Chief Scientific Officer, Vionelix Pharmaceuticals
Member	Dr Edward Bush BSc PhD	Principal Scientist – Pharmacopoeial Specialist, Chemical Development, AstraZeneca
Member	Dr Ka Lung Chan⁴ PhD DIC MRSC	Reader in Pharmaceutical Molecular Spectroscopy, Kings College London, Head of the Medicine Development Department
Member	Mr Carlo Emanuele Giartosio MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Member	Dr Janet Halliday⁵ BSc PhD FRPharmS	Former Associate Vice President, Ferring Controlled Therapeutics

³ Reappointed 22/06/2024

⁴ Appointed 03/06/2024

⁵ Appointed 03/06/2024

Member	Dr Vikas Jaitely⁶ BPharm MPharm PhD MRPharmS GPhC MTOPRA	Director (EU Digital Healthcare & Devices), Global Regulatory Affairs, Merck
Member	Mr Sean Jones BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and St. Thomas' NHS Foundation Trust
Member	Dr Oisin Kavanagh⁷ MPharm PhD SFHEA FRPharmS	Senior Lecturer in Pharmaceutics, Newcastle University
Member	Dr Majella Lane⁸ BSc PhD FAPS	Associate Professor and Director of the Skin Research Group, University College London
Member	Dr Paul Marshall⁹ BPharm PhD MRPharmS MAPS FTOPRA	Director, Global Regulatory Affairs, Jazz Pharmaceuticals

⁶ Reappointed 22/06/2024

⁷ Appointed 03/06/2024

⁸ Appointed 03/06/2024

⁹ Reappointed 22/06/2024

Member	Professor Yvonne Perrie ¹⁰ BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Member	Mr James Rickard MPharm	Chief Scientific Officer, Richmond Research Institute; Visiting Senior Lecturer, Kings College, London
Member	Professor Monique Simmonds OBE JP BSc PhD FLS FBS FRES FWIF	Deputy Director of Science, Royal Botanic Gardens, Kew

¹⁰ Appointed 03/06/2024

Membership of the Anti-Infective Medicines Expert Advisory Group (AIM EAG)

Post	Name and title	Affiliations
Chair	Dr Rodney Horder⁺ BPharm, PhD, MRPharmsS	Former Vice President, Strategic Regulatory Affairs, Europe, Abbott Laboratories
Vice Chair	Dr Graham Cook⁺ PhD	Consultant
Member	Mr Faraat Ali¹¹ BPharm MRPharm PGDDRA PGDM	Research Scientist, Department of Analytical Chemistry, Charles University, Czech Republic
Member	Mr Greg Blake⁺ MRSC, CChem	Site Director GSK Worthing
Member	Mr Eamon Flahive⁺ B.Sc, HDAS (Ap.Sci), PDRA	Former Director and Head of Regulatory Affairs, Elanco Animal Health
Member	Dr Vikas Jaitely⁺ BPharm	Director (EU Digital Healthcare & Devices),

⁺ Reappointed 01/01/2024

¹¹ Appointed 01/01/2024

	MPharm PhD MRPharmS GPhC MTOFRA	Global Regulatory Affairs, Merck
Member	Mr Sean Jones⁺ BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and St. Thomas' NHS Foundation Trust
Member	Dr John Miller PhD	Retired. Professor, Strathclyde University

Membership of the Biological and Biotechnological Products Expert Advisory Group (BIO EAG)

Post	Name and title	Affiliations (if applicable)
Chair	Dr Anna-Maria Brady⁺ BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Vice Chair	Dr Emre Amirak⁺ BSc MBBS MRCS	Chief Medical Officer, Proveca Limited; Chief Medical Officer & Chief Scientific Officer, Vionelix Pharmaceuticals
Member	Mr Simeon Gill BPharm MSc AMIChemE	Director, CMC Regulatory Affairs, AstraZeneca
Member	Dr Lyn Healy¹² BSc MSc PhD CSci FRSB	Principal Laboratory Research Scientist Human Embryo and Stem Cell Unit, The Francis Crick Institute

⁺ Reappointed 01/01/2024

¹² Appointed 01/01/2024

Member	Dr Ahmed Keed ¹³ BSc	QC Compliance Senior Specialist, Polpharma Biologics Company, Gdansk Site, Poland
Member	Dr Garry Lavery ¹⁴ PhD MPharm FHEA MRSC	Senior Lecturer in Pharmaceutical Sciences, School of Pharmacy, Queen's University Belfast
Member	Dr Brij Patel BPharm MRPharmS PhD	RegExcel Consulting Ltd.
Member	Mr Lionel Randon MSc	Head of GRA CMC Regulatory Intelligence, Merck KGaA, Switzerland
Member	Dr Robin Thorpe PhD FRCPPath	Fellow of the Royal College of Pathologists Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control
Member	Mr Paolo Tozzi ¹⁵ MSc	Global QC Director Pharmacopoeia Affairs

¹³ Appointed 01/01/2024

¹⁴ Appointed 01/07/2024

¹⁵ Appointed 01/01/2024

		and External Engagement Moderna Inc
Member	Dr Lincoln Tsang BPharm LLB PhD FRSC FRPharmS FRSB FRSA Solicitor	Partner and Head of Life Sciences Practice, Ropes & Gray LLP
Member	Dr Paul Varley PhD	Senior Vice President Development, Alchemab Therapeutics

Membership of the Herbal and Complementary Medicines Expert Advisory Group (HCM EAG)

Post	Name and title	Affiliations
Chair	Professor Monique Simmonds OBE JP BSc PhD FLS FBS FRES FWIF	Deputy Director of Science, Royal Botanic Gardens, Kew
Vice Chair	Dr Dick Middleton ⁺ PhD, MPhC	Director, British Herbal Medicine Association
Member	Mr Paul Anderson ⁺ BSc CBIOL MRSB	Head of Compliance, G R Lane Health Products Ltd.
Member	Dr Anthony Booker ⁺ MSc, PhD, MRSC, FLS	Reader in Ethnopharmacology, University of Westminster Honorary Lecturer UCL School of Pharmacy Associate Editor, Frontiers in Ethnopharmacology Fellow of The Linnean Society
Member	Dr Christopher Etheridge ⁺ PhD MRSC MCPP CChem DoIC ARCS BSc	Chair of the British Herbal Medicine Association, President of the European Herbal and Traditional Medicine Association,

	(Hons) Chem BSc (Hons) Phyto	President of the College or Practitioners of Phytotherapy, Director of the European Scientific Cooperative on Phytotherapy, Member of the Royal Society of Chemistry, Chartered Chemist, medical herbalist.
Member	Dr Christine Leon¹⁶ PhD	Honorary Research Associate (Chinese Medicinal Plants), Royal Botanic Gardens, Kew
Member	Mr Barry Moore⁺ BSc MSc	Regulatory Affairs Consultant – Herbals, Bath
Member	Dr Eike Reich⁺ PhD	Retired.
Member	Dr Michael Rowan¹⁷ PhD	Formerly University of Bath
Member	Professor Adrian Slater⁺ BSc MSc PhD	Emeritus Professor, Faculty of Health and Life Sciences, De Montfort University

¹⁶ Stepped down 05/2024

¹⁷ Resigned 03/2024

⁺ Reappointed 01/01/2024

Member	Professor Katja Strohfeldt ⁺ PhD, PGCAP, MRSC, PFHEA	Professor in Pharmaceutical Chemistry and Education (School of Pharmacy, University of Reading), Associate Pro-Vice Chancellor, Vice-Chancellor's Office, University of Reading
Member	Dr Ruben Thanacoody ⁺ PGCertEd MD FRCP FRCP(Edin)	Consultant Physician, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust Honorary Clinical Senior Lecturer in Clinical Pharmacology, Newcastle University Honorary Consultant Clinical Toxicologist, UK Health Security Agency Director National Poisons Information Service (Newcastle unit)
Member	Mr Clive Welham ⁺ MRSC	Technical Manager, Ransom Naturals Ltd.
Member	Professor Elizabeth Williamson ⁺	Retired. Former Emeritus Professor of Pharmacy, The School of Pharmacy, University of Reading

	BSc(Pharm) PhD	
Member	Dr Kaicun Zhao⁺ MB MM PhD	Retired. Former Programme Leader in Chinese Herbal Medicine Department of Mental Health, Social Work and Integrative Medicine School of Health, Social Care & Education, Middlesex University London

Membership of the Medicinal Chemicals Expert Advisory Group (MC1 EAG)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall⁺ BPharm PhD MRPharmS MAPS FTOPRA	Director, Global Regulatory Affairs, Jazz Pharmaceuticals
Vice Chair	Dr Edward Bush⁺ BSc PhD	Principal Scientist – Pharmacopoeial Specialist, Chemical Development, AstraZeneca
Member	Dr Varada Bapat¹⁸ BPharm MPharm PhD	Chief Operating Officer, RV Lifesciences Ltd, India
Member	Dr John Berridge⁺ BSc PhD FRSC	Independent Pharmaceutical Consultant
Member	Mr Seamus Boland¹⁹ BSc	Analytical Science & Technology Specialist, SGS International Service Laboratories

¹⁸ Appointed 01/01/2024

⁺ Reappointed 01/01/2024

¹⁹ Appointed 01/01/2024

Member	Professor Donald Cairns⁺ BSc (Hons), PhD FRPharmS FRSC.	Professor Emeritus, School of Pharmacy and Life Sciences, Robert Gordon University
Member	Mr Adrian Caws⁺ GRSC PGDip	Retired
Member	Mr Paul Fleming⁺ BPharm MSc MRPharmS	Technical Director for Medicines UK
Member	Dr John Lough⁺ PhD	Programme Leader, MSc Drug Discovery and Development, University of Sunderland
Member	Mr Dave Malpas⁺ BSc MRSC CChem.	Pharmaceutical Consultant
Member	Mr Steven Nolan⁺ MChem, MRSC	QP Consultant/Director, United QP Consulting Ltd

Membership of the Medicinal Chemicals Expert Advisory Group (MC2 EAG)

Post	Name and title	Affiliations
Chair	Dr Graham Cook⁺ PhD	Consultant
Vice Chair	Mr Chris Goddard⁺ BSc DIS CSci CChem FRSC	Analytical Consultant
Vice Chair	Mr James Rickard⁺ MPharm	Chief Scientific Officer, Richmond Research Institute; Visiting Senior Lecturer, Kings College, London
Member	Mr Mohamed Abdelhamid Ali²⁰ BPharm TQM	QC/R&D Head, Sunny Pharmaceutical
Member	Professor James Birchall⁺ B.Pharm.(Hons) , Ph.D., FHEA	Deputy Head of School School of Pharmacy and Pharmaceutical Sciences College of Biomedical and Life Sciences

²⁰ Appointed 01/01/2024

Member	Mr James Cowie⁺ BSc	Formerly Regulatory Facilitator and lead of Analytical Science and Technology Team at Novartis Grimsby Ltd
Member	Ms Karen Foster⁺ MSc FRSC C.Chem	Group Scientist Quality Expert, PHC Global Product Stewardship. Procter & Gamble Technical Centres
Member	Mr Elliot Hook⁺ MChem	QC Analytical Standards Senior Lead, GSK
Member	Dr John Miller⁺ PhD	Retired. Professor, Strathclyde University
Member	Mr Shekhar Natarajan²¹ BSc MSc FRSC FTOPRA	Vice President - Regulatory Affairs, Dyne Therapeutics
Member	Dr Andrea Ruggiero⁺ PhD	Director - GRA CMC Regulatory Intelligence, Merck KGaA

⁺ Reappointed 01/01/2024

²¹ Appointed 01/01/2024

Member	Dr Zena Smith²² BSc, PhD	Senior Director, Regulatory CMC Jazz Pharmaceuticals
Corresponding Member	Dr Marius Brits⁺ B.Pharm, M.Sc PhD	Associate Professor: Pharmaceutics North- West University, School of Pharmacy, Potchefstroom - South Africa

²² Appointed 01/01/2024

Membership of the Medicinal Chemicals Expert Advisory Group (MC3 EAG)

Post	Name and title	Affiliations
Interim Chair	Mr Ian Williams BSc, MSc	Former Quality Director Sumitomo Pharmaceuticals Europe Ltd.
Co-vice Chair	Mr Carlo Emanuele Giartosio²³ MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Co-vice Chair	Mr Chris Goddard⁺ BSc DIS CSci CChem FRSC	Analytical Consultant
Member	Mr Martin Coxon²⁴ MChem ARCS	Analytical Development Manager, Custom Pharma Services
Member	Ms Karen Foster⁺ MSc FRSC C.Chem	Group Scientist Quality Expert, PHC Global Product Stewardship. Procter & Gamble Technical Centres

²³ Appointed 01/01/2024

⁺ Reappointed 01/01/2024

²⁴ Appointed 01/01/2024

Member	Mr Phil Hampshire⁺ BSc Hons	QC Analytical Support Senior Team Leader, Accord Healthcare.
Member	Dr Majella Lane²⁵ BSc PhD FAPS	Associate Professor and Director of the Skin Research Group at University College London
Member	Mr Jigar P. Mehta²⁶ M.Sc.	Deputy General Manager, (Subject Matter Expert Analytical/Quality), Zydus Lifesciences Ltd Member of Stakeholder Engagement Planning Committee in US Pharmacopoeia. Reviewer for monograph and guidance in International Pharmacopoeia (WHO).
Member	Ms Desireen Nader Obaid²⁷ MPharm	Scientific Affairs Manager, Joswe Medical Pharmaceuticals
Member	Mr Ron Torano⁺ BSc PhD, MRSC	Former Process Owner, Quality Regulatory

²⁵ Appointed 01/01/2024

²⁶ Appointed 01/01/2024

²⁷ Appointed 01/01/2024

		Intelligence, GlaxoSmithKline
--	--	----------------------------------

Membership of the Pharmacy and Nomenclature Expert Advisory Group (PCN EAG)

Post	Name and title	Affiliations
Chair	Dr Jeff Aronson⁺ MA, DPhil, MBChB, FRCP, HonFFPM, HonFBPhS	Hon Consultant Physician and Clinical Pharmacologist, Centre for Evidence Based Medicine
Vice Chair	Mr Robert Lowe⁺ BPharm FRPharmS	Director of Pharmacy Quality Assurance Specialist Services, NHS East of England & Northamptonshire
Member	Dr Adam Brelsford²⁸ MPharm PhD	Senior Clinical Writer – Pharmaceutical Press, Royal Pharmaceutical Society
Member	Dr David Elder⁺ PhD, FRSC, CChem	Independent CMC consultant
Member	Dr Rodney Horder⁺ BPharm, PhD, MRPharmsS	Former Vice President, Strategic Regulatory Affairs, Europe, Abbott Laboratories

⁺ Reappointed 01/01/2024

²⁸ Appointed 01/01/2024

Member	Dr Oisin Kavanagh ²⁹ MPharm PhD SFHEA FRPharmS	Senior Lecturer in Pharmaceutics, Newcastle University
Member	Mr John McGuire ⁺ BSc MSc	Regulatory Affairs Director
Member	Dr Gerard P Moss ⁺ BSc, PhD ARCS	Emeritus Senior Lecturer in Organic Chemistry, Queen Mary University of London
Member	Professor Kevin Taylor ⁺ BPharm, PhD, FRPharmS	Emeritus Professor, University College London
Member	Dr Robin Thorpe ⁺ PhD FRCPATH	Fellow of the Royal College of Pathologists Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control

²⁹ Appointed 01/01/2024

Membership of the Unlicensed Medicines Expert Advisory Group (ULM EAG)

Post	Name and title	Affiliations
Chair	Mr Robert Lowe BPharm FRPharmS	Director of Pharmacy Quality Assurance Specialist Services, NHS East of England & Northamptonshire
Member	Mr Alex Bosley⁺ BPharm MRPharmS	Lead Qualified Person & Pharmacist, Torbay Pharmaceuticals Ltd
Member	Mr Wayne Goddard⁺ MSc	Education & Training Lead – Pharmacy & Quality Control North Tees & Hartlepool NHS Foundation Trust
Member	Ms Sarah Hartley⁺ BSc (Hons)	Manager Analytical R&D Rosemont Pharmaceuticals Ltd
Member	Mr Joaquim Ramada- Magalhes BSc, MSc, CChem, CSci, MRSC	Associate Director, Global Quality Compliance, Lonza Senior QA Manager (Consultant), St Barts NHS Trust – Nuclear Medicine & Radiopharmacy

Member	Dr Julian Smith⁺ PhD MRPharmS	Director at JCS Pharma Consulting Ltd
Member	Mr Andrew Sully⁺ BPharm MRPharmS	Principal Pharmacist Quality Control & Qualified Person, Cardiff and Vale University Health Board
Member	Mr Adam Walker³⁰ MPharm MRPharmS	Head of Quality, North East and North Cumbria Aseptic Medicines Production Hub, Qualified Person at Newcastle Advanced Therapies and Newcastle Specials

Membership of the Panel of Experts for Blood Products (BLP Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Varley PhD	Senior Vice President Development, Alchemab Therapeutics
Member	Mr James Rickard MPharm	Chief Scientific Officer, Richmond Research

⁺ Reappointed 01/01/2024

³⁰ Appointed 01/01/2024

		Institute; Visiting Senior Lecturer, Kings' College, London
--	--	--

Membership of the Panel of Experts for Excipients (CX Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall BPharm PhD MRPharmS MAPS FTOPRA	Director, Global Regulatory Affairs, Jazz Pharmaceuticals
Member	Professor Hannah Batchelor BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde
Member	Dr Richard Cawthorne BSc PhD CChem MRSC	Research and Technology Fellow, Croda Europe
Member	Dr Oisin Kavanagh ³¹ MPharm PhD	Senior Lecturer in Pharmaceutics, Newcastle University

³¹ Appointed 01/01/2024

	SFHEA FRPharmS	
Member	Mr Chris Turville ³² MSci MRSC MRQA	Raw Materials Team Leader, Wrafton Laboratories Ltd (trading as Perrigo)

Membership of the Panel of Experts for Inorganic and General Chemicals (IGC Panel)

Post	Name and title	Affiliations
Chair	Mr Chris Goddard ⁺ BSc DIS CSci CChem FRSC	Analytical Consultant
Member	Mr Seamus Boland ⁺ BSc	Analytical Science & Technology Specialist. SGS International Service Laboratories.
Member	Mr Peter Henrys ⁺ BSc	IGC Panel Member QRA Technical Manager, BOC Healthcare
Member	Dr Majella E. Lane ³³ BSc PhD FAPS	Associate Professor and Director of the Skin

³² Appointed 01/01/2024

³³ Appointed 01/01/2024

		Research Group, University College London
--	--	---

Membership of the Panel of Experts for Microbiology (MIC Panel)

Post	Name and title	Affiliations
Chair	Dr Vikas Jaitely⁺ BPharm MPharm PhD MRPharmS GPhC MTOGRA	Director (EU Digital Healthcare & Devices), Global Regulatory Affairs, Merck
Member	Dr Miriam Guest⁺ PhD	Senior Principal Scientific Advisor, Charles River Labs, Microbial Solutions
Member	Dr Carol Iversen⁺ PhD CBiol MRSB MISTR	Associate Scientific Director, BioReliance (a Merck KGaA company)
Member	Dr Joao Inacio Silva⁺ PhD FHEA	Principal Lecturer Pharmaceutical Microbiology, School of Applied Sciences, University of Brighton

Membership of the Panel of Experts for Radioactive Materials (RAD Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall ³⁴ BPharm PhD MRPharmS MAPS FTOPRA	Director, Global Regulatory Affairs, Jazz Pharmaceuticals
Member	Dr Rebekka Hueting ³⁵ MChem DPhil MRSC	Radiopharmaceutical Unit Lead, Wales Research and Diagnostic PET Imaging Centre, Cardiff University
Member	Dr Roger Pickett ⁺ B.Pharm, Ph.D.	Retired

⁺ Reappointed 01/01/2024

³⁴ Appointed Acting Chair 01/01/2024

³⁵ Appointed 01/01/2024

Membership of the Panel of Experts for Veterinary Medicines (VET Panel)

Post	Name and title	Affiliations
Chair	Professor Elizabeth Williamson⁺ BSc(Pharm) PhD	Emeritus Professor of Pharmacy, The School of Pharmacy, University of Reading
Member	Mr Andrew Cairns⁺ BSc	Murray Farmcare Ltd. Industry liaison
Member	Dr Sarah Cockbill⁺ PhD, BPharm, MPharm, LL.M, DAgVetPharm, FRPharmS, FVPA	Honorary Lecturer Cardiff School of Pharmacy and Pharmaceutical Services Cardiff University
Member	Mr David Evans⁺ BPharm	Pharmacist
Member	Mr Eamon Flahive⁺ B.Sc, HDAS (Ap.Sci), PDRA	Former Director and Head of Regulatory Affairs, Elanco Animal Health

⁺ Reappointed 01/01/2024

Membership of the Panel of Experts for Veterinary Immunological Products (VIP Panel)

Post	Name and title	Affiliations
Chair	Dr Anna-Maria Brady⁺ BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Member	Dr Rory Cooney B.Sc. M.Sc. Ph.D	Head of Biologicals Section at the Veterinary Medicines Directorate
Member	Dr Martin Ilott⁺ BVSc PhD MRCVS	Retired. Former Efficacy and Safety Director, Australian Pesticides and Veterinary Medicines Authority
Member	Dr Catrina Stirling⁺ BSc (Hon) PhD	Director Regulatory Affairs Zoetis
Member	Dr Ralph Woodland⁺ BSc PhD	Former Senior Assessor in Biologicals Assessment Team, Veterinary Medicines Directorate

Membership of the Analytical Quality by Design Working Party (AQbD WP)

Post	Name and title	Affiliations
Chair	Dr Graham Cook PhD	Consultant
Member	Dr Phil Borman DSc CChem FRSC	Director & Senior Fellow, QbD Platforms & Acceleration, GlaxoSmithKline
Member	Dr Stephen L R Ellison FRSC CChem	Chief Metrologist & Science Fellow, National Measurement Laboratory, LGC Ltd, Guildford
Member	Dr Peter Hamilton PhD	Head of Product and Process Control, AstraZeneca, UK
Member	Professor Melissa Hanna-Brown PhD	Professor of Analytical Chemistry (Futures Pharmaceuticals), University College Cork
Member	Mr Sean Jones BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and

		St. Thomas' NHS Foundation Trust
Member	Dr Rosario LoBrutto PhD MBA MS	Vice President, Global Technical Operations Ironwood Pharmaceuticals, Boston, USA
Member	Dr John Lough PhD	Programme Leader, MSc Drug Discovery and Development, University of Sunderland
Member	Dr Tina Morris Ph.D.	Executive Director, American Association of Pharmaceutical Scientists (AAPS)
Member	Dr Phil Nethercote BS PhD	Retired
Member	Dr Mustafa Zaman BPharm (Hons) PhD MRPharmS	Senior Consultant, Granzer Regulatory Consulting and Services GmbH; Visiting Senior Lecturer, King's College, London

Corresponding Member	Dr Kimber Barnett PhD	Former Research Fellow, Pfizer, Groton, USA
Corresponding Member	Mr Brent Harrington MS	Senior Director and Drug Product Statistics Lead, Pfizer Research and Development, PSSM Data Sciences, Groton, CT

Membership of Advanced Therapy Medicinal Products Working Party (ATMP WP)

(incorporating the sub-groups on (i) Flow Cytometry, (ii) Vector Copy Number, (iii) Empty Capsids for AAV Products and (iv) T Cell and NK Cell Characterisation Assays)

Post	Name and title	Affiliations
Chair	Dr Jacqueline Barry⁺ PhD	Chief Clinical Officer, Cell and Gene Therapy Catapult
Member	Dr Ian Anderson⁺ PhD	Senior Global Principal Scientist, Lonza
Member	Dr Clare Blue⁺ Ph.D	Senior CMC Translation Consultant, eXmoor Pharma Concepts Ltd.
Member	Dr Sam Brocklehurst³⁶ PhD	Senior Scientist, Pharmaron Biologics (UK) Ltd.
Member	Dr John Campbell⁺ PhD FRSB	Chemokine Research Group, School of Infection and Immunity College of Medical, Veterinary and Life Sciences University of Glasgow

⁺ Reappointed 01/01/2024

³⁶ Appointed 01/07/2024

Member	Dr Paul Carter⁺ BSc	Senior Director MSAT, Quell Therapeutics
Member	Dr David Caulfield⁺ MD	NHS
Member	Dr Michel Degueudre³⁷ PhD	Gene Therapy Biophysical Sciences Lead, Analytical Development Sciences, Patient Supply, UCB
Member	Dr Leanne Di Rollo³⁸ BSc PhD	Associate Director, Regulatory Affairs, IQVIA
Member	Dr Sabine Domning³⁹ Dpl Dr.rer.nat.	King's College London
Member	Dr Peter Emery-Billcliff⁺ PhD, BSc	Principal Scientist and Lab Manager, Complement Therapeutics
Member	Dr Alicja Fiedorowicz⁺ MSc	Senior Consultant, Dark Horse Consulting

³⁷ Appointed 01/07/2024

³⁸ Appointed 01/01/2024

³⁹ Appointed 01/01/2024

Member	Dr Paul Getty ⁺ BSc (Hons), PhD	Senior Technical Specialist, Pharmaron Biologics (UK) Ltd.
Member	Dr Kimberly Gilmour ⁺ Ph.D., FRCPath	Chief of Laboratory Medicine, Consultant Clinical Scientist, Clinical Lead Immunology and Director of Cell Therapy Camelia Botnar Laboratories Great Ormond Street Hospital for Children NHS Foundation Trust
Member	Dr Alan Griffith ⁴⁰ PhD	Head of Global Operations, VectorBuilder
Member	Dr Zara Hannoun ⁺ PhD	Senior Scientist at Zelluna Therapeutics, Oslo Norway
Member	Dr Lyn Healy ⁴¹ BSc MSc PhD CSci FRSB	Principal Laboratory Research Scientist Human Embryo and Stem Cell Unit, The Francis Crick Institute
Member	Mr Tishwant Kanwarjit ⁺ MPharm PgDip	Executive Director, Site Head of Quality, Autolus

⁴⁰ Appointed 01/07/2024

⁴¹ Appointed 01/01/2024

Member	Dr Ishtiaq Khaliq ⁴² BSc, MSc, PhD	Lead Gene Therapy Molecular Biology Sciences. GT Analytical Sciences, UCB, Brain l'Alleud, Belgium
Member	Dr Lily Li ⁺ PhD	Lead Scientist, AviadoBio
Member	Dr Archie Lovatt ⁺ BSc(Hons) PhD	Health & Nutrition Health Sciences - Scientific Operations Director, Biosafety & Characterisation Services - Cell Banks, Biologics, Vectors & Vaccines
Member	Dr Mark Lowdell ⁺ PhD FRCPATH FRSI	Professor of Cell & Tissue Therapy, UCL
Member	Dr Keith McLuckie BSc, PhD	Head of Non-Clinical Cell and Gene Therapy Catapult
Member	Dr Ramon Mendoza ⁴³ BS MS PhD	Scientist, Analytical Development Advanced Therapies, Janssen

⁴² Appointed 01/07/2024

⁺ Reappointed 01/01/2024

⁴³ Appointed 01/07/2024

		Johnson & Johnson Innovative Medicine
Member	Dr Josefina Nilsson PhD	CEO of Qutem, Sweden
Member	Dr Rickard Nordstrom⁺ PhD	Chief Operating Officer, QuTEM.
Member	Dr Jeffrey Patrick⁴⁴ PhD	Senior Director Operations, CMC BioAnalytical
Member	Dr Leonard Pattenden⁺ PhD	CEO, CMC Biopharma Ltd, UK
Member	Dr Stuart Paul-Adams⁺ FRCPath	Consultant Clinical Scientist (SIHMDS- Haematology), Joint Trust Lead Healthcare Scientist, Honorary Associate Professor (Infect, Imm, Infla. & Physio Med, UCL), Level 2 Camelia Botnar Laboratory, Great Ormond Street Hospital
Member	Dr Jasbir Rattu⁺ MPharm PhD MRSC	Consultant Industrial Pharmacist ATMP

⁴⁴ Appointed 01/07/2024

	MRPharmS MCQI CQP	Qualified Person (QP), CeutiQus
Member	Mr Ian Rees⁺ BSc	Regulatory Affairs Consultant, D.I., Rees Ltd
Member	Dr Rita Rego⁺ PhD MRSB QP	Senior Vice President (SVP), Quality at ViroCell Biologics, Ltd
Member	Dr Sushmita "Mimi" Roy⁴⁵ PhD	Founder & Principal, Ion Bio Enterprises, San Rafael, USA
Member	Dr Chaminda Salgado⁺ BSc	CMC Innovation Lead, CEPI (Coalition for Epidemic Preparedness and Innovation
Member	Dr Franz Schnetzing⁺ PhD	CMC Technology Lead, CEPI UK Ltd Independent Consultant
Member	Miss Isobel Searing⁺ BMedSc	Director of QC, Replimune Inc.
Member	Dr Beata Surmacz- Cord⁺ MSc, PhD, CMgr CMIFellow	Study Delivery Leader, GlaxoSmithKline
Member	Dr Huimin (Helen) Tao⁺ PhD	Associate Director ADO Molecular Biology, Novartis Gene Therapies, USA

⁴⁵ Appointed 01/07/2024

Member	Mr Paolo Tozzi ⁴⁶ MSc	Global QC Director Pharmacopoeia Affairs and External Engagement, Moderna Inc.
Member	Dr Christian van den Bos ⁴⁷ PhD	Managing Director, Mares ITX GmbH, Germany
Member	Dr Peng Wang ⁺ PhD	Lonza Houston Inc.
Member	Dr Wei Wang ⁺ BSc MSc PhD	Principal Scientist, Analytical Development, Autolus Therapeutics
Member	Dr Caroline Weydert ⁺ PharmD PhD	EMEA Sales Specialist Genomics - Biopharma Bio-Rad Laboratories N.V
Member	Dr Wei Zhang ⁴⁸ PhD	Senior Scientist, GMU next generation sequencing group, Sanofi

⁴⁶ Appointed 01/07/2024

⁴⁷ Appointed 01/07/2024

⁺ Reappointed 01/01/2024

⁴⁸ Appointed 01/07/2024

Membership of Alternative Approaches for Documentary and Physical Standards for Biotechnological Products Working Party (BIO-DPS WP)

Post	Name and title	Affiliations
Chair	Dr Paul Varley⁺ PhD	Senior Vice President Development, Alchemab Therapeutics
Vice Chair	Dr Anna-Maria Brady⁺ BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Member	Dr Laurent Duhau⁺ PhD	Sanofi R&D, Global CMC Development, Global Head of BioAnalytics
Member	Mr Carlo Emanuele Giartosio⁺ MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Member	Dr Friederike Plath⁺ PhD	Senior Scientist, Pharmaceutical Technical Development Europe, F. Hoffmann-La Roche Ltd, Switzerland

Member	Dr Alla Polozova ⁴⁹ PhD	Director, Attribute Sciences, Process Development, Amgen
Member	Dr Ash Ramzan ⁺ PhD, FTOPRA	Principal Consultant, Woodley Bioreg Ltd.

EUROPEAN PHARMACOPOEIA COMMISSION – Members of the United Kingdom Delegation During 2024

	Name	Affiliations
Main	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Main	Mr Robert Lowe BPharm FRPharmS	Director of Pharmacy Quality Assurance Specialist Services, NHS East of England & Northamptonshire
Main	Mr Stephen Hoare	Head of Standards & Regulatory Governance, Medicines and

⁴⁹ Appointed 01/01/2024

		Healthcare products Regulatory Agency (MHRA)
Alternates	Mr Peter Crowley	Head of BP & Labs, MHRA
Alternates	Mr Stephen Young	Head of BP/Labs Team, MHRA

DECLARATION OF INTERESTS

British Pharmacopoeia Commission, BPC's Expert Advisory Groups members, Working Parties and Panels of Experts have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Memb er	Comm ittee	Intere st Type	Compan y / Organisa tion / Sponsor	Nature of Interest	Curr ent	Additional Informatio n
Adam Brelsfo rd	PCN EAG	Person al	NIL	N/A	N/A	
Adam Brelsfo rd	PCN EAG	Non- Person al	NIL	N/A	N/A	
Adam Walker	ULM EAG	Person al	NIL	N/A	N/A	
Adam Walker	ULM EAG	Non- Person al	NIL	N/A	N/A	

Adrian Caws	MC1 EAG	Personal	GSK	Shares	Yes	
Adrian Caws	MC1 EAG	Personal	Haleon	Shares	Yes	
Adrian Caws	MC1 EAG	Non-Personal	NIL	N/A	N/A	
Adrian Caws	MC1 EAG	Additional				Immediate family member holds shares in GSK and Haleon
Adrian Slater	HCM EAG	Personal	Mycorrhizal Systems	Consultancy on DNA barcoding and metagenomics	Yes	
Adrian Slater	HCM EAG	Non-Personal	NIL	N/A	N/A	

Ahmed Keed	BIO EAG	Personal	POL Pharma Biologics Gdansk site	Salary	Yes
Ahmed Keed	BIO EAG	Non-Personal	NIL	N/A	N/A
Alan Griffith	WP ATMP	Personal	NIL	N/A	N/A
Alan Griffith	WP ATMP	Non-Personal	NIL	N/A	N/A
Alex Bosley	ULM EAG	Personal	Torbay Pharmace uticals Ltd	Salaried QP for company	Yes
Alex Bosley	ULM EAG	Non-Personal	NIL	N/A	N/A
Alicja Fiedorowicz	WP ATMP	Personal	Dark Horse Consultin g	Shares	Yes

Alicja Fiedorowicz	WP ATMP	Personal	Pfizer	Shares	Yes	
Alicja Fiedorowicz	WP ATMP	Non-Personal	NIL	N/A	N/A	
Alla Polozova	WP BIO-DPS	Personal	Amgen	Salary, Shares	Yes	
Alla Polozova	WP BIO-DPS	Personal	Astra Zeneca	Shares	Yes	
Alla Polozova	WP BIO-DPS	Non-Personal	NIL	N/A	N/A	
Alla Polozova	WP BIO-DPS	Additional				Member of non-profit industry trade groups, including IQ Consortium and IPSE.

Participate on a volunteer basis and don't acquire any compensation.

Andrea Ruggiero	MC2 EAG	Personal	Merck KGaA	Consultancy, Salary	Yes
Andrea Ruggiero	MC2 EAG	Non-Personal	NIL	N/A	N/A
Andrew Cairns	Panel VET	Personal	NIL	N/A	N/A
Andrew Cairns	Panel VET	Non-Personal	NIL	N/A	N/A
Andrew Sully	ULM EAG	Personal	NIL	N/A	N/A

Andre w Sully	ULM EAG	Non- Person al	NIL	N/A	N/A
Anna- Maria Brady	BPC, BIO EAG, WP BIO- DPS, Panel VIP	Person al	GSK	Immediat e family member holds shares	Yes
Anna- Maria Brady	BPC, BIO EAG, WP BIO- DPS, Panel VIP	Person al	Astra Zeneca	Immediat e family member holds shares	
Anna- Maria Brady	BPC, BIO EAG, WP BIO- DPS,	Non- Person al	NIL	N/A	

	Panel VIP					
Anna- Maria Brady	BPC, BIO EAG, WP BIO- DPS, Panel VIP	Additional				I am an editorial board member of the journal Biologicals as well as an occasional reviewer and editor. This is an unpaid position.
Anthony Booker	HCM EAG	Personal	NIL	N/A	N/A	
Anthony Booker	HCM EAG	Non- Personal	NIL	N/A	N/A	

Anthon y Booker	HCM EAG	Additio nal				The British Herbal Medicine Associatio n and The European Herbal Practitione rs Associatio n provide some funding to the University of Westminst er in the form of student bursaries.
-----------------------	------------	----------------	--	--	--	---

Archie Lovatt	WP ATMP	Person al	SGS	Employe e	Yes
Archie Lovatt	WP ATMP	Non- Person al	NIL	N/A	N/A

Ash Ramza n	WP BIO- DPS	Person al	NIL	N/A	N/A
Ash Ramza n	WP BIO- DPS	Non- Person al	NIL	N/A	N/A
Barry Moore	HCM EAG	Person al	Herbal Reality (herbal medicine advocacy)	Fees – writing scientific content and articles for website	No
Barry Moore	HCM EAG	Person al	Vivian Rolfe (individua l start up business)	Consulta ncy	No
Barry Moore	HCM EAG	Person al	Sebastia n Pole (individua l start up business)	Consulta ncy	No

Barry Moore	HCM EAG	Personal	Cambridge Tea Consultancy	Consultancy	No
Barry Moore	HCM EAG	Non-Personal	NIL	N/A	N/A
Beata Surmacz-Cordle	WP ATMP	Personal	GSK	Shares, Salary	Yes
Beata Surmacz-Cordle	WP ATMP	Non-Personal	NIL	N/A	N/A
Brent Harrington	WP AQbD	Personal	Pfizer Inc.	Salary	Yes
Brent Harrington	WP AQbD	Non-Personal	NIL	N/A	N/A
Brij Patel	BIO EAG	Personal	Various	Consultancy	Yes

Brij Patel	BIO EAG	Personal	Various legal firms	Consultancy	Yes
Brij Patel	BIO EAG	Personal	Pfizer	Immediate family employment and shares	Yes
Brij Patel	BIO EAG	Non-Personal	NIL	N/A	N/A
Carlo Emanuele Giartosio	BPC, MC3 EAG, BIO-DPS WP	Personal	NIL	N/A	N/A
Carlo Emanuele Giartosio	BPC, MC3 EAG, BIO-DPS WP	Non-Personal	NIL	N/A	N/A

Carol Iverson	Panel MIX	Personal	Bioreliance - a company of Merck KGAA	Salary	Yes
Carol Iverson	Panel MIX	Non-Personal	NIL	N/A	N/A
Caroline Weydert	WP ATMP	Personal	Bio-Rad Laboratories	Salary and bonus	Yes
Caroline Weydert	WP ATMP	Personal	Pfizer	Shares	Yes
Caroline Weydert	WP ATMP	Non-Personal	NIL	N/A	N/A
Catrina Stirling	Panel VIP	Personal	Zoetis	Employment and shares	Yes

Catrina Stirling	Panel VIP	Non-Personal	NIL	N/A	N/A	
Catrina Stirling	Panel VIP	Additional				Member of and now chair of the Animal Health Europe Technical and Regulatory committee.
Chami nda Salgado	WP ATMP	Personal	NIL	N/A	N/A	
Chami nda Salgado	WP ATMP	Non-Personal	NIL	N/A	N/A	
Chandrashekar (Shekar)	MC2 EAG	Personal	Dyne Therapeutics	Salaried as full-time employee	Yes	

Natarajan

Chandrashekar (Shekar) Natarajan	MC2 EAG	Conference / Scientific Meetings	DIA (Drug Information Association)	Japan Annual Meeting 2024: Attended this event as regular attendee after paying the registration fee	No
----------------------------------	---------	----------------------------------	------------------------------------	--	----

Chandrashekar (Shekar) Natarajan	MC2 EAG	Conference / Scientific Meetings	DIA (Drug Information Association)	Japan Annual Meeting 2025: Attended this event as regular attendee after	No
----------------------------------	---------	----------------------------------	------------------------------------	--	----

				paying the registrati on fee	
Chandr ashekh ar (Shekh ar) Nataraj an	MC2 EAG	Non- Person al	NIL	N/A	N/A
Chris Etherid ge	HCM EAG	Person al	BHMA	Chair of the BHMA – receive monthly honorariu m.	Yes
Chris Etherid ge	HCM EAG	Person al	UK TIA	Independ ent consultan cy.	Yes
Chris Etherid ge	HCM EAG	Non- Person al	NIL	N/A	N/A

Chris Goddard	MC2 EAG, MC3 EAG, Panel IGC	Personal	QMS	I am an analytical consultant working for QMS Ltd who in turn are working for RPH Pharmaceuticals	Yes
Chris Goddard	MC2 EAG, MC3 EAG, Panel IGC	Non-Personal	NIL	N/A	N/A
Chris Turville	MC3 EAG, CX Panel	Personal	Wrafton Laboratories Trading as Perrigo	Salary	Yes
Chris Turville	MC3 EAG,	Personal	Amazon. com Inc	Shares	No

	CX Panel					
Chris Turville	MC3 EAG, CX Panel	Person al	Alphabet	Shares	No	
Chris Turville	MC3 EAG, CX Panel	Person al	NVIDIA Corporati on	Shares	No	
Chris Turville	MC3 EAG, CX Panel	Non- Person al	NIL	N/A	N/A	
Christi an van den Bos	WP ATMP	Person al	NIL	N/A	N/A	
Christi an van den Bos	WP ATMP	Non- Person al	NIL	N/A	N/A	
Christi an van	WP ATMP	Additio nal				We operate a consultanc

den
Bos

y (Mares
ITX
GmbH)
which
provides
services to
organizations in the
pharmaceutical
space. At
current,
this
includes
development of a
AAV
product
with a
large
pharma
client.

Christi
ne
Leon

HCM
EAG

Personal
NIL

N/A

N/A

Christine Leon	HCM EAG	Non-Personal	NIL	N/A	N/A	
Claire Nicholson	BPC	Personal	NIL	N/A	N/A	
Claire Nicholson	BPC	Non-Personal	NIL	N/A	N/A	
Clare Blue	WP ATMP	Personal	eXmoor Pharma	Full time employee in role of CMC consultant	Yes	As a consultant to external CGT Companies some of the content defined within the ATMP working group (analytical guidance) may apply to these

companies

·
Additionally as
eXmooR
also
serves as
a CDMO
and
supporting
Clients
through
process
development
projects
some of
the
content
discussed
within the
ATMP
working
group may
also apply
to these
activities.

Clare Blue	WP ATMP	Non- Person al	NIL	N/A	N/A
Clive Welham	HCM EAG	Person al	Ransom Naturals Ltd	Salary	Yes
Clive Welham	HCM EAG	Non- Person al	NIL	N/A	N/A
Dave Malpas	MC1 EAG	Person al	Sanofi	Sharehol der	Yes
Dave Malpas	MC1 EAG	Person al	HALEON	Sharehol der	Yes
Dave Malpas	MC1 EAG	Person al	Euroapi	Sharehol der	Yes
Dave Malpas	MC1 EAG	Person al	GSK	Sharehol der	Yes
Dave Malpas	MC1 EAG	Non- Person al	NIL	N/A	N/A
David Caulfield	WP ATMP	Person al	Caulfield Pharma Consultin g	Owner, director, sharehol	Yes

				der and employee	
David Caulfiel d	WP ATMP	Person al	Autolus	Consulta ncy and Sharehol der	Yes
David Caulfiel d	WP ATMP	Person al	Pfizer	Consulta ncy	Yes
David Caulfiel d	WP ATMP	Person al	Kings University GVTF	Consulta ncy	Yes
David Caulfiel d	WP ATMP	Person al	Roche	Consulta ncy	Yes
David Caulfiel d	WP ATMP	Non-Person al	NIL	N/A	N/A
David Elder	PCN EAG	Person al	David P Elder Consulta ncy	Providing paid consultan cy for CMC (chemistr y,	Yes

manufact
uring &
controls)
issues

David Elder	PCN EAG	Person al	GSK	Shares	Yes
David Elder	PCN EAG	Person al	Astra Zeneca	Shares	Yes
David Elder	PCN EAG	Person al	Abbvie	Shares	Yes
David Elder	PCN EAG	Person al	Amolyt	CMC consultan cy	Yes
David Elder	PCN EAG	Person al	Compass	CMC consultan cy	Yes
David Elder	PCN EAG	Person al	Istesso	CMC consultan cy	Yes
David Elder	PCN EAG	Person al	Cerebro	CMC consultan cy	Yes

David Elder	PCN EAG	Personal	Kanna	CMC consultancy	Yes	
David Elder	PCN EAG	Personal	Eliquent	CMC consultancy	Yes	
David Elder	PCN EAG	Personal	Firebrick	CMC consultancy	Yes	
David Elder	PCN EAG	Non-Personal	NIL	N/A	N/A	
David Elder	PCN EAG	Additional				I write a regular foreward for European Pharmaceutical Review (EPR) on various topics of interest to readers, e.g., the

role of AI
in
pharmace
utical
industry.
these
articles are
wholly
crafted by
me and
EPR does
not
influence
my output
nor pay
me.

I regularly
review
articles in
various
journals,
e.g.,
journal of
pharmace
utical
sciences,

organic
process
research
and
developme
nt, journal
of
chromatog
raphy.

These are
blind
reviews
and my
participatio
n isn't
recorded
in the
published
article.

I'm not
paid for
these
reviews.

Desire en Nader Obaid	MC3 EAG	Person al	Joswe Medical (Generic) Industries	Salary	Yes
Desire en Nader Obaid	MC3 EAG	Non- Person al	NIL	N/A	N/A
Dick (Richar d) Middlet on	MC3 EAG	Person al	Herbal Medicine s Regulator y Services Ltd	Director/ Company dividends	Yes
Dick (Richar d) Middlet on	MC3 EAG	Person al	Diapharm UK Ltd	UK Responsi ble Person for Medical Devices held by Diapharm GmbH	Yes

Dick (Richard) Middleton	MC3 EAG	Personal	Dr Loges GmbH	National Contact Person for UK Pharmac ovigilanc e	Yes
Dick (Richard) Middleton	MC3 EAG	Personal	British Herbal Medicine Associati on	Director of Trade Associati on represent ing herbal medicine manufact urers	Yes
Dick (Richard) Middleton	MC3 EAG	Non- Personal	NIL	N/A	N/A
Donald Cairns	MC1 EAG	Personal	NIL	N/A	N/A

Donald Cairns	MC1 EAG	Non- Person al	NIL	N/A	N/A
Eamon Flahive	AIM EAG, Panel VET	Person al	Eli Lilly & Co	Shares	Yes
Eamon Flahive	AIM EAG, Panel VET	Person al	Elanco Animal Health	Shares	Yes
Eamon Flahive	AIM EAG, Panel VET	Person al	Aenorasi s S.A.	Consulta ncy	Yes
Eamon Flahive	AIM EAG, Panel VET	Non- Person al	NIL	N/A	N/A
Edward Bush	BPC, MC1 EAG	Person al	AstraZene ca Pharmace uticals	Employe d by AstraZen eca as a Principal Scientist	Yes

				and own a limited number of shares in this company	
Edward Bush	BPC, MC1 EAG	Non- Person al	NIL	N/A	Yes
Eike Reich	HCM EAG	Person al	NIL	N/A	N/A
Eike Reich	HCM EAG	Non- Person al	NIL	N/A	N/A
Elizabeth William son	EAG HCM, Panel VET	Person al	NIL	N/A	N/A
Elizabeth William son	EAG HCM, Panel VET	Non- Person al	NIL	N/A	N/A
Elliot Hook	MC2 EAG	Person al	GSK	Salary, shares	Yes

Elliot Hook	MC2 EAG	Personal	Haleon	shares	Yes
Elliot Hook	MC2 EAG	Non-Personal	NIL	N/A	N/A
Emre Amirak	BPC, BIO EAG	Personal	Proveca Limited	Salary, Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Vionelix Pharmaceuticals	Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Sanofi	Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Proveca Pharma Limited	Subsidiary of Proveca Limited	Yes
Emre Amirak	BPC, BIO EAG	Non-Personal	NIL	N/A	N/A
Faraat Ali	AIM EAG	Personal	NIL	N/A	N/A

Faraat Ali	AIM EAG	Non- Person al	NIL	N/A	N/A
Franz Schnetzinger	WP ATMP	Person al	CEPI UK Ltd	Salary and pension entitleme nt	Yes
Franz Schnetzinger	WP ATMP	Person al	Independ ent Consulta nt	Consulta ncy fees	Yes
Franz Schnetzinger	WP ATMP	Non- Person al	NIL	N/A	N/A
Friederike Plath	WP BIO- DPS	Person al	F. Hoffmann -La Roche Ltd., Switzerlan d	Salary	Yes
Friederike Plath	WP BIO- DPS	Non- Person al	NIL	N/A	N/A

Garry Lavery	BIO EAG	Personal	Resilient Pharma Ltd	Director, launched spin-out company from Queen's University Belfast. Currently dormant. In place to hold any intellectual property that may arise from Dr Lavery's research.	Yes
--------------	---------	----------	----------------------	--	-----

Garry Lavery	BIO EAG	Personal	ViiV Healthcare/GSK	Involved in using drug donated by ViiV Healthcare	Yes
--------------	---------	----------	---------------------	---	-----

e with my drug delivery system to explore it's use in HIV prevention.

Garry Lavery	BIO EAG	Non-Personal	NIL	N/A	N/A
Gerard Moss	PCN EAG	Personal	WHO	Proof reading pINN lists before publication	No
Gerard Moss	PCN EAG	Personal	AMA	Name and structure of chemical USANs	No

Gerard Moss	PCN EAG	Non- Person al	NIL	N/A	N/A
Graham Cook	AIM EAG, MC2 EAG, WP AQbD	Person al	Pfizer	Shares, Salary	Yes
Graham Cook	AIM EAG, MC2 EAG, WP AQbD	Person al	Viatrix	Shares	Yes
Graham Cook	AIM EAG, MC2 EAG, WP AQbD	Non- Person al	NIL	N/A	N/A
Greg Blake	AIM EAG	Person al	GSK	Shares & Salary	Yes

Greg Blake	AIM EAG	Non- Person al	NIL	N/A	N/A
Hanna h Batchel or	CX Panel	Person al	NIL	N/A	N/A
Hanna h Batchel or	CX Panel	Non- Person al	UCB	Grant awarded to support a PhD student under my supervisi on	No
Hanna h Batchel or	CX Panel	Non- Person al	GSK	Grant awarded to support a PhD student under my supervisi on	Yes

Hayley BPC Hall	Person al	Flatiron Health UK (an independ ent affiliate of the Roche group)	I am a lay member of the research transpare ncy panel at Flatiron Health UK which is an independ ent affiliate of the Roche group. My role in this panel is solely related to issues of data access to Flatiron Health UK'S	Yes
--------------------	--------------	---	---	-----

trusted
research
environm
ent of UK
Cancer
Data.
Paid role.

Hayley BPC Non- NIL
Hall Person
 al

Hayley BPC Additio
Hall nal

University
of Central
Lancashire
– from
December
2020
Member of
the Ethics
Communit
y, paid
role, not
related to
a product.

Hayley Hall	BPC	Additional				Durham University – from June 2024 Member of the Ethics Community, unpaid role, not related to a product.
Huimin (Helen) Tao	WP ATMP	Personal	Novartis	Salary, shares	Yes	
Huimin (Helen) Tao	WP ATMP	Personal	Fate Therapeutics	Shares	Yes	
Huimin (Helen) Tao	WP ATMP	Personal	MNPR	Shares	Yes	
Huimin (Helen) Tao	WP ATMP	Personal	ALT	Shares	Yes	

Huimin (Helen) Tao	WP ATMP	Non- Person al	NIL	N/A	N/A
Ian Anders on	WP ATMP	Person al	Lonza	Salary	Yes
Ian Anders on	WP ATMP	Non- Person al	NIL	N/A	N/A
Ian William s	AIM EAG, MC3 EAG	Person al	Viatrix	Shares	Yes
Ian William s	AIM EAG, MC3 EAG	Non- Person al	NIL	N/A	N/A
Ishtiaq Khaliq	WP ATMP	Person al	USB	Salary	Yes
Ishtiaq Khaliq	WP ATMP	Non- Person al	NIL	N/A	N/A

Isobel Searing	WP ATMP	Personal	Oxford Biomedica	Shares	Yes
Isobel Searing	WP ATMP	Personal	Replimune Ltd	Salary, Share options and RSUS	Yes
Isobel Searing	WP ATMP	Non-Personal	NIL	N/A	N/A
James Birchall	MC2 EAG	Personal	AstraZeneca	Shareholding	Yes
James Birchall	MC2 EAG	Personal	Avaxzipen	Member Advisory Board	Yes
James Birchall	MC2 EAG	Non-Personal	NIL	N/A	N/A
James Cowie	MC2 EAG	Personal	Novartis Pharma AG	Consultancy	No

James Cowie	MC2 EAG	Personal	Novartis Pharma AG	Salary	No
James Cowie	MC2 EAG	Non- Personal	NIL	N/A	N/A
James Rickard	BPC, MC2 EAG, BLP Panel	Personal	Biotherap y Services Ltd	Salary & Shares	Yes
James Rickard	BPC, MC2 EAG, BLP Panel	Personal	Richmon d Research Institute	Salary	Yes
James Rickard	BPC, MC2 EAG, BLP Panel	Personal	Amylyx Pharmace uticals	Shares	Yes
James Rickard	BPC, MC2 EAG,	Personal	BioMarin Pharmace uticals	Shares	Yes

	BLP Panel				
James Rickard	BPC, MC2 EAG, BLP Panel	Non- Person al	NIL	N/A	N/A
Janet Halliday	BPC, ULM EAG	Person al	Calla Lily Clinical Care	Share options, Consultan cy, Expenses	Yes
Janet Halliday	BPC, ULM EAG	Person al	Alveus	Consulta ncy	Yes
Janet Halliday	BPC, ULM EAG	Confer ence/S cientifi c Meetin gs	Sponsor: Call Lily Clinical Care	Speakers Fee	No
Janet Halliday	BPC, ULM EAG	Non- Person al	NIL	N/A	N/A

Jasbir Rattu	ATMP WP	Personal	NIL	N/A	N/A
Jasbir Rattu	ATMP WP	Non-Personal	NIL	N/A	N/A
Jeff Aronson	PCN EAG	Personal	NIL	N/A	N/A
Jeff Aronson	PCN EAG	Non-Personal	NIL	N/A	N/A
Jeffrey Patrick	ATMP WP	Personal	NIL	N/A	N/A
Jeffrey Patrick	ATMP WP	Non-Personal	NIL	N/A	N/A
Jigar P. Mehta	MC3 EAG	Personal	NIL	N/A	N/A
Jigar P. Mehta	MC3 EAG	Non-Personal	NIL	N/A	N/A

Joao Inacio Silva	PANEL MIC	Personal	NIL	N/A	N/A
Joao Inacio Silva	PANEL MIC	Non-Personal	NIL	N/A	N/A
Joaquim Ramada-Magalhaes	ULMEAG	Personal	Lonza Biologics Plc	Salary	Yes
Joaquim Ramada-Magalhaes	ULMEAG	Non-Personal	NIL	N/A	N/A
John Berridge	MC1EAG	Personal	NIL	N/A	N/A
John Berridge	MC1EAG	Non-Personal	NIL	N/A	N/A

John Campbell	WP ATMP	Personal	Resolution Therapeutics	Consultancy, Shareholding	Yes
John Campbell	WP ATMP	Personal	Adthera Bio Ltd	Consultancy, Shareholding	Yes
John Campbell	WP ATMP	Personal	Swarm Oncology Ltd	Consultancy, Shareholding	Yes
John Campbell	WP ATMP	Personal	Lift Biosciences Ltd	Consultancy, Shareholding	Yes
John Campbell	WP ATMP	Personal	Cellular Origins Ltd	Consultancy	Yes
John Campbell	WP ATMP	Non-Personal	NIL	N/A	N/A
John Lough	MC1 EAG,	Personal	NIL	N/A	N/A

WP
AQbD

John Lough	MC1 EAG, WP AQbD	Confer ence/S cientifi c Meetin gs	So far only instrumen t vendor companie s have paid to exhibit	Chromat ographic Society Spring Symposi um: No benefit to member; only to The Chromat ographic Society for which the member is a member of the Executive Committe e.	No
---------------	---------------------------	---	---	---	----

John Lough	MC1 EAG, WP AQbD	Non- Person al	NIL	N/A	N/A	
John Lough	MC1 EAG, WP AQbD	Additio nal	Elsevier			Authored a book chapter on “British Pharmaco poeia” prepared
John McGuire	PCN EAG	Person al	AstraZen eca	Employee, salary, sharehol dings and dividends	Yes	
John McGuire	PCN EAG	Non- Person al	NIL	N/A	N/A	
John Miller	AIM EAG, MC2 EAG	Person al	NIL	N/A	N/A	

John Miller	AIM EAG, MC2 EAG	Non-Personal	NIL	N/A	N/A
Josefina Nilsson	WP ATMP	Personal	QuTEM AB	Shares and Salary	Yes
Josefina Nilsson	WP ATMP	Non-Personal	NIL	N/A	N/A
Julian Smith	ULM EAG	Personal	JCS Pharma Consulting Ltd	Director, Consultant and Shareholder	Yes
Julian Smith	ULM EAG	Personal	Reckitt Benckiser Group Plc	Shares	Yes
Julian Smith	ULM EAG	Non-Personal	NIL	N/A	N/A
Ka Lung Andre	BPC	Personal	NIL	N/A	N/A

w
Chan

Ka Lung Andre w Chan	BPC	Confer ence/S cientifi c Meetin gs	Joint Pharmac eutical Analysis Group	Joint Pharmac eutical Analysis Group (JPAG) meetings: Free registrati on to JPAG meetings	Yes
----------------------	-----	---	--	--	-----

Ka Lung Andre w Chan	BPC	Confer ence/S cientifi c Meetin gs	APS/JPA G	APS (UKPhar m Sci) annual meeting: Free registrati on to the meeting. Travel expenses	No
----------------------	-----	---	--------------	---	----

Ka Lung Andre w Chan	BPC	Non- Personal	NIL	N/A	N/A
----------------------	-----	---------------	-----	-----	-----

Ka Lung Andre w Chan	BPC	Additional			I am an academic at King’s College London and I conduct research. One of my research activities involves collaborating with a pharmaceutical company (Astra Zeneca) on a drug development project
----------------------	-----	------------	--	--	---

in which I am the second supervisor of a PhD student (co-funded by the UKRI and AstraZeneca). The start date and duration of the project will be on the 01 Oct 2024 for 4 years.

At King's College London, I give lectures on the British Pharmacology

poeia (a total of 4 hours per year) at the master and undergraduate levels. I also provide training to master students on how to use and critique the BP monographs.

Ka Lung Andre w Chan	BPC	Additional
----------------------	-----	------------

I am a committee member of a Royal Society of Chemistry

interest group (the Joint Pharmaceutical and Analysis Group). I helped organising meetings (7 per year) and occasionally join as an invited speaker.

Kaicun Zhao	HCM EAG	Personal	NIL	N/A	N/A
Kaicun Zhao	HCM EAG	Non-Personal	NIL	N/A	N/A
Karen Foster	MC2 EAG, MC3 EAG		P&G	Salary	Yes

Karen Foster	MC2 EAG, MC3 EAG	Non-Personal	NIL	N/A	N/A
Katja Strohfeldt	HCM EAG	Personal	NIL	N/A	N/A
Katja Strohfeldt	HCM EAG	Non-Personal	NIL	N/A	N/A
Kevin Taylor	PCN EAG	Personal	NIL	N/A	N/A
Kevin Taylor	PCN EAG	Non-Personal	NIL	N/A	N/A
Kimber Barnett	WP AQbD	Personal	Pfizer	Salary, Shares	Yes
Kimber Barnett	WP AQbD	Personal	Various pharmaceutical companies /industry	Shares managed by others: shares included in mutual	Yes

funds
and
shares
actively
managed
by
advisors

Kimber Barnett	WP AQbD	Non-Personal	NIL	N/A	N/A
----------------	---------	--------------	-----	-----	-----

Kimber Barnett	WP AQbD	Additional			Volunteer and member of the USP Expert Committee on Measurement and Data Quality
----------------	---------	------------	--	--	--

Kimberly Gilmour	WP ATMP	Personal	NIL	N/A	N/A
------------------	---------	----------	-----	-----	-----

Kimberly Gilmour	WP ATMP	Confere nces/Scientific Meetings	Paediatric Rheumatology Society	PRES2024: Travel and conference fees	No
Kimberly Gilmour	WP ATMP	Non-Personal	NIL	N/A	N/A
Lauren Duhaut	WP BIO-DPS	Personal	Sanofi	Salary and shares	Yes
Lauren Duhaut	WP BIO-DPS	Non-Personal	NIL	N/A	N/A
Leanne DiRollo	WP ATMP	Personal	IQVIA	Salary (full time position)	Yes
Leanne DiRollo	WP ATMP	Non-Personal	NIL	N/A	N/A
Len Patten	WP ATMP	Personal	Fondazione Telethon	Consultancy – Head of CMC	Yes

Len Patten den	WP ATMP	Personal	Symmetric Events	Consultancy – provide training in CMC and regulatory facets of ATMPs	Yes
Len Patten den	WP ATMP	Personal	Ascend Advanced Therapies	Co-founder – share grant (company is not public yet).	No
Len Patten den	WP ATMP	Personal	Ascend Advanced Therapies	Shareholder	Yes
Len Patten den	WP ATMP	Non- Personal	NIL	N/A	N/A

Lily Li	WP ATMP	Person al	Catapult	Salary through employ ment	No
Lily Li	WP ATMP	Person al	AviadoBi o	Salary and shares through employ ment	Yes
Lily Li	WP ATMP	Confere nces/Sc ientific Meeting s	Oxford Global	Fees – waivered due to being speaker	No
Lily Li	WP ATMP	Confere nces/Sc ientific Meeting s	AviadoBi o	5th Gene Therapy Analytical Develop ment Europe 2024 - Fees paid by employer for	No

				attendance	
Lily Li	WP ATMP	Non- Personal	NIL	N/A	N/A
Lincoln Tsang	BIO EAG	Personal	Ropes & Gray LLP	Partner and Head of European Life Sciences of the law firm advising life sciences and healthcar e industry on various legal matters. Professio nal and ethical	Yes

rules governing the legal profession require client confidentiality. No nature of interest can be disclosed.

Lincoln Tsang	BIO EAG	Non-Personal	NIL	N/A	N/A
Lionel Randon	BIO EAG	Personal	Merck KGaA	Salary	Yes
Lionel Randon	BIO EAG	Non-Personal	NIL	N/A	N/A

Lionel Randon
BIO EAG
Additional

EDQM
Expert in
the MAB
Working
Party
since 2016
and
General
Method
Working
Party
since 2018
Member of
EFPIA
since 2009
involved in
the
Manufactu
ring &
Quality,
Biomanufa
cturing
and
Pharmaco
poeias
expert
Groups

Lyn Healy BIO EAG, WP ATMP Personal NIL N/A N/A

Lyn Healy BIO EAG, WP ATMP Non-Personal NIL N/A N/A

Majella Lane BPC, MC3 EAG, Panel IGC Personal NIL N/A N/A

Majella Lane BPC, MC3 EAG, Panel IGC Non-Personal NIL N/A N/A

Majella Lane BPC, MC3 EAG, Panel IGC Additional I have established a limited company called Melderm Ltd. The company

provides expert witness services for patent matters in the United States.

Marius Brits	MC2 EAG	Personal	NIL	N/A	N/A
Marius Brits	MC2 EAG	Conference/Scientific Meetings	Sponsor: WHO	Travel, accommodation and per diem to attend WHO Expert Committee meetings in Geneva, Switzerland, as I am a member	Yes

of the
WHO
Expert
Committee
on
Specifications
Meetings
and
Consultations.

Marius
Brits

MC2
EAG

Non-
Personal

WHO

Financial support provided by WHO to the North-West University to provide technical assistance (laboratory work and monographs)

Yes

h
 developm
 ent) for
 the
 developm
 ent of
 pharmaco
 peial
 monograp
 hs for
 publicatio
 n in The
 Internatio
 nal
 Pharmaco
 poeia of
 the WHO.

Mark Lowdel I	WP ATMP	Person I	BitBio Ltd	Member of SAB, consultant	Yes
Mark Lowdel I	WP ATMP	Person al	Autolus Ltd	Consulta nt	Yes
Mark Lowdel I	WP ATMP	Person al	INmune Bio Inc	Co- founder, co-	Yes

				director, CSO, sharehol der, consultan t	
Mark Lowdel I	WP ATMP	Person al	Achilles Tx Ltd	Co- founder, Sharehol der, Consulta nt	No
Mark Lowdel I	WP ATMP	Person al	Avectas Ltd	Chair of SAB, Consulta nt	Yes
Mark Lowdel I	WP ATMP	Person al	BioRecell Ltd	Member of SAB, Consulta nt	Yes
Mark Lowdel I	WP ATMP	Person al	NWBioth erapeutic s Inc	Consulta nt	Yes

Mark Lowdel I	WP ATMP	Personal	Sartorius GmbH	Member of SAB	Yes
Mark Lowdel I	WP ATMP	Personal	Virocell Ltd	Shareholder	Yes
Mark Lowdel I	WP ATMP	Non-Personal	INmune Bio Inc	Grant to support PhD student under my supervision at University College London	No
Martin Coxon	MC3 EAG	Personal	Custom Pharma Services	salary - work at company that manufactures these products.	Yes

Martin Coxon	MC3 EAG	Non- Person al	NIL	N/A	N/A
Martin Ilott	Panel VIP	Person al	NIL	N/A	N/A
Martin Ilott	Panel VIP	Non- Person al	NIL	N/A	N/A
Meliss a Hanna- Brown	WP AQbD				
Michae l Rowan	HCM EAG	Person al	NIL	N/A	N/A
Michae l Rowan	HCM EAG	Non- Person al	NIL	N/A	N/A
Michel Deguel dre	WP ATMP	Person al	UCB	Salary	Yes
Michel Deguel dre	WP ATMP	Non- Person al	NIL	N/A	N/A

Michel WP Additio
Deguel ATMP nal
dre

I am an effective member of the Belgian Society for Mass Spectrometry (BSMS). The Society receives sponsorship from many sources for its annual congress. These funds are shared between the local organising committee

who run the conference and BSMS to grant students for international congress attendance and to promote mass spectrometry in general.

Miriam Guest	Panel MIC	Personal	AstraZeneca	Employee	No
Miriam Guest	Panel MIC	Personal	AstraZeneca	Shareholder	Yes
Miriam Guest	Panel MIC	Personal	Charles River Labs,	Employee	Yes

			Microbial Solutions		
Miriam Guest	PANEL MIC	Non-Personal	NIL	N/A	N/A
Mohamed Abdelhamid Ali	MC2 EAG	Personal	Sunny Pharmaceutical	Salary	Yes
Mohamed Abdelhamid Ali	MC2 EAG	Non-Personal	NIL	N/A	N/A
Monique Simmonds	BPC, HCM EAG	Personal	Polypharmakos Limited	Director, no financial etc interest	Yes
Monique Simmonds	BPC, HCM EAG	Conference/Scientific	Sponsor: Proctor and Gamble	Costs for travel covered	No

Meetings

Monique Simmonds BPC, HCM EAG Non-Personal P&G Master collaboration agreement grant (no personal consultancy) Yes

Monique Simmonds BPC, HCM EAG Additional Member of Defra Darwin Initiative Advisory Committee no financial etc interest

Monique Simmonds BPC, HCM EAG Additional Member of Grantham Centre for Sustainable Futures, no

Monique BPC, Additio
e HCM nal
Simmonds EAG

financial
etc interest
Past
President
of Good
Practice
Traditional
Chinese
Medicine
Research
Associatio
n, no
financial
etc interest

Monique BPC, Additio
e HCM nal
Simmonds EAG

Chair of
Hilliers
Gardens
Trust
Advisory
Board, no
financial
etc interest

Monique BPC, Additio
e HCM nal
Simmonds EAG

Member of
Hong
Kong Dept
of Health,

Pharmacopoeia International Advisory Committee, no financial etc interest

Monique BPC, Additional
e HCM nal
Simmonds EAG

Member of Responsible Beauty Advisory Council (P&G), no financial etc interest

Monique BPC, Additional
e HCM nal
Simmonds EAG

Member of Royal Holloway University of London Department of Health Advisory Board, no

financial
etc interest

Mustafa Zaman	WP AQbD	Personal	Granzery Consulting and Services GmbH, Germany. https://www.granzery.biz/index.html	Employee	Yes
---------------	---------	----------	--	----------	-----

Mustafa Zaman	WP AQbD	Conferences/Scientific Meetings	King's College London	MPharm undergraduate (3rd year) lecture. presented lecture 'on-line'.	No
---------------	---------	---------------------------------	-----------------------	---	----

Mustafa Zaman	WP AQbD	Conferences/Scientific	King's College London	Pharmaceutical sciences MSc	No
---------------	---------	------------------------	-----------------------	-----------------------------	----

		Meetings		course lecture. presented lecture	
Mustafa Zaman	WP AQbD	Non-Personal	NIL	N/A	N/A
Mustafa Zaman	WP AQbD	Additional			Lecturer (honorary) at Kingston University. This is an unpaid post.
Mustafa Zaman	WP AQbD	Additional			Visiting (Honorary) senior lecturer at King's College London for both MPharm and MSc programm

es.
This is an
unpaid
post.
Senior
Lecturer
(honorary)
De
Montfort
University.

Mustafa
Zaman
WP
AQbD
Additional

This is an
unpaid
post.
Member
Centre of
Pharmace
utical
Medicine
Research
(CPMR)
Scientific
Advisory
Board,
King's
College

Mustafa
Zaman
WP
AQbD
Additional

London.

This is an
unpaid
post

Oisin Kavanagh	BPC, CX Panel, PCN EAG	Personal	NIL	N/A	N/A
-------------------	------------------------------------	----------	-----	-----	-----

Oisin Kavanagh	BPC, CX Panel, PCN EAG	Non- Personal	Thiogenes s Therapeuti cs	Grant funding	No
-------------------	------------------------------------	------------------	------------------------------------	------------------	----

Paolo Tozzi	BIO EAG, WP ATMP	Personal	Moderna	Shares	Yes
----------------	---------------------------	----------	---------	--------	-----

Paolo Tozzi	BIO EAG, WP ATMP	Personal	Novartis	Shares	Yes
----------------	---------------------------	----------	----------	--------	-----

Paolo Tozzi	BIO EAG, WP ATMP	Non-Personal	NIL	N/A	N/A	
Paolo Tozzi	BIO EAG, WP ATMP	Additional				I am part also of CTP, GTP and mRNA working groups in EDQM and of the mRNA expert committee in USP
Paul Anderson	HCM EAG	Personal	GR Lane Health Products Ltd	Salary	Yes	
Paul Anderson	HCM EAG	Non-Personal	NIL	N/A	N/A	

Paul Carter	WP ATMP	Personal	Quell Therapeutics	Salary and shares	Yes
Paul Carter	WP ATMP	Personal	GSK	Shares	Yes
Paul Carter	WP ATMP	Personal	AstraZeneca	Shares	Yes
Paul Carter	WP ATMP	Non-Personal	NIL	N/A	N/A
Paul Fleming	MC1 EAG	Personal	Medicines UK (formerly BGMA, British Generic Manufacturers Association)	Technical Director of a pharmaceutical industry trade association	Yes
Paul Fleming	MC1 EAG	Non-Personal	NIL	N/A	N/A
Paul Getty	WP ATMP	Personal	Pharmon Biologics	Salary	Yes

Paul Getty	WP ATMP	Non- Person al	NIL	N/A	N/A
Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Person al	Jazz Pharmace uticals	Shares & Employment	Yes
Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Person al	Reckitt Benckiser Plc	Shares	Yes
Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Person al	Individior	Shares	Yes

Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Confer ences/ Scientifi c Meetin gs	TOPRA	TOPRA: Presenter Expense s	No
Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Confere nces/Sc entific Meeting s	Nexus	Presenter Expense s	No
Paul Marsha II	BPC, MC1 EAG, Panel RAD, CX Panel	Confere nces/Sc entific Meeting s	Oxford Global	Presenter Expense s	No
Paul Marsha II	BPC, MC1 EAG, Panel RAD,	Non- Person al	NIL	N/A	N/A

	CX Panel				
Paul Varley	BIO EAG, BLP Panel, WP BIO- DPS	Person al	Sanofi	Shares	Yes
Paul Varley	BIO EAG, BLP Panel, WP BIO- DPS	Person al	Alchem a b	Salary	Yes
Paul Varley	BIO EAG, BLP Panel, WP BIO- DPS	Person al	Various research stage Biotechs	Consulta ncy	Yes
Paul Varley	BIO EAG, BLP Panel,	Non- Person al	NIL	N/A	N/A

	WP BIO- DPS				
Peng Wang	WP ATMP	Person al	Lonza	Salary	Yes
Peng Wang	WP ATMP	Non- Person al	NIL	N/A	N/A
Peter Emery- Billcliff	WP ATMP	Person al	GSK	Shares	Yes
Peter Emery- Billcliff	WP ATMP	Person al	Haleon	Shares	Yes
Peter Emery- Billcliff	WP ATMP	Person al	Complem ent Therapeu tics	EMI Share Option and Salary	Yes
Peter Emery- Billcliff	WP ATMP	Confer ences/ Scientifi c Meetin gs	Sartorius Progen Promega RapidMic ro Systems Advance	GENE THERAP Y DEVELO PMENT 2024: Expense	No

d
 Instrume
 nts
 Benchling
 Biocair
 NOF
 Corporati
 on
 TATAA
 Biocentre
 SGS

s paid by
 employer
 Complem
 ent
 Therapeu
 tics

Peter Emery- Billcliff	WP ATMP	Confer ences/ Scientifi c Meetin gs	Platinum Sponsors Anemocy te Aseptic Technolo gies Charles River Exothera LumaCyt e MaxCyte PlasmiDF actory Refeyn	European Society for Gene and Cell Therapy 2024: Expense s paid by employer Complem ent Therapeu tics; conferen ce provided	No
------------------------------	------------	--	---	--	----

Reithera
Sartorius
Viralgen
...and
many
more

Peter Emery-Billcliff	WP ATMP	Non-Personal	NIL	N/A	N/A
-----------------------	---------	--------------	-----	-----	-----

Peter Hamilton	WP AQbD	Personal	AstraZeneca	Salary, Shares	Yes
----------------	---------	----------	-------------	----------------	-----

Peter Hamilton	WP AQbD	Personal	NIL	N/A	N/A
----------------	---------	----------	-----	-----	-----

Peter Henrys	Panel IGC	Personal	BOC Ltd.	Salary	Yes
--------------	-----------	----------	----------	--------	-----

Peter Henrys	Panel IGC	Personal	NIL	N/A	N/A
--------------	-----------	----------	-----	-----	-----

Peter Henrys	Panel IGC	Additional			Chairman of the European Pharmacopoeia 9G
--------------	-----------	------------	--	--	---

Medical
Gas
Committee

·
Chairman
of British
Compress
ed Gas
Associatio
n (BCGA)
Medical
Gas
Committee
(TSC7)
Member of
European
Industrial
Gas
Associatio
n (EIGA)
Medical
Gas
Committee
(WG7) and
Medical
Gas
Equipment

Committee
(WG15)
Chairman
of BSI CH
121 / SC6
Standards
Committee
(Medical
Gas
Supply
Systems)
Member of
ISO TC
121 / SC6
Standards
Committee
(Medical
Gas
Supply
Systems)
Member of
the
Associatio
n of
Anesthetis
ts Safety
Committee

Financial Director (Non-Paid) of BAREMA (British Anaesthetic and Respiratory Equipment Manufacturing Association)

Phil Borman	WP AQbD	Personal	GSK	Salary and Shares	Yes
Phil Borman	WP AQbD	Non-Personal	NIL	N/A	N/A
Phil Hampshire	MC3 EAG	Personal	Accord Healthcare	Salary	Yes

Phil Hamps hire	MC3 EAG	Non- Person al	NIL	N/A	N/A	
Phil Nether cote	WP AQbD	Person al	NIL	N/A	N/A	
Phil Nether cote	WP AQbD	Non- Person al	NIL	N/A	N/A	
Phil Nether cote	WP AQbD	Additio nal				I am Co Editor of Method Validation in Pharmace utical Analysis
Ralph Woodl and	Panel VIP	Person al	NIL	N/A	N/A	
Ralph Woodl and	Panel VIP	Non- Person al	NIL	N/A	N/A	

Ralph Woodland	Panel VIP	Additional				Immediate family member works for AstraZeneca
Ramon Mendoza	WP ATMP	Personal	NIL	N/A	N/A	
Ramon Mendoza	WP ATMP	Non-Personal	NIL	N/A	N/A	
Rebeka Hueting	Panel RAD	Personal	NIL	N/A	N/A	
Rebeka Hueting	Panel RAD	Non-Personal	NIL	N/A	N/A	
Richard Cawthorne	CX Panel	Personal	Croda International Plc	Shares	Yes	

Richard Cawthorne	CX Panel	Personal	Croda International Plc	Consultancy	Yes
Richard Cawthorne	CX Panel	Personal	Croda International Plc	Salary	No
Richard Cawthorne	CX Panel	Non-Personal	NIL	N/A	N/A
Rickard Nordstrom	WP ATMP	Personal	QuTEM AB	Shares and Salary	Yes
Rickard Nordstrom	WP ATMP	Non-Personal	NIL	N/A	N/A
Rita Rego	WP ATMP	Personal	Virocell Biologics Ltd	Salary and Shares	Yes
Rita Rego	WP ATMP	Personal	Qualis Pharma Solutions Ltd	Director of the consultanc	Yes

				by company	
Rita Rego	WP ATMP	Non- Personal	NIL	N/A	N/A
Robert Lowe	BPC, PCN EAG, ULM EAG	Personal	NIL	N/A	N/A
Robert Lowe	BPC, PCN EAG, ULM EAG	Non- Personal	NIL	N/A	N/A
Robin Thorpe	BIO EAG, PCN EAG	Personal	NIL	N/A	N/A
Robin Thorpe	BIO EAG, PCN EAG	Non- Personal	NIL	N/A	N/A
Rodney Horder	AIM EAG, PCN EAG	Personal	Blackrock Pharmaceuti- cals	Consultan- cy	No

Rodney Horder	AIM EAG, PCN EAG	Non-Personal	NIL	N/A	N/A
Roger Pickett	Panel RAD	Personal	GE Healthcare	Shares & Pension	Yes
Roger Pickett	Panel RAD	Personal	GE Healthcare	Immediate family member holds shares	Yes
Roger Pickett	Panel RAD	Non-Personal	NIL	N/A	N/A
Ronald Torano	MC3 EAG	Personal	GSK	Pension and shares	Yes
Ronald Torano	MC3 EAG	Non-Personal	NIL	N/A	N/A
Rosario LoBrutto	WP AQbD	Personal	Pharma Vision LLC	Consultancy	Yes
Rosario LoBrutto	WP AQbD	Non-Personal	NIL	N/A	N/A

Ruben Thanacody	HCM EAG	Personal	NIL	N/A	N/A
Ruben Thanacody	HCM EAG	Non-Personal	NIL	N/A	N/A
Sabine Domning	WP ATMP	Personal	NIL	N/A	N/A
Sabine Domning	WP ATMP	Non-Personal	NIL	N/A	N/A
Sam Brocklehurst	WP ATMP	Personal	Pharmaron	Salary, Shares	Yes
Sam Brocklehurst	WP ATMP	Non-Personal	NIL	N/A	N/A
Sarah Cockbill	Panel VET	Personal	NIL	N/A	N/A
Sarah Cockbill	Panel VET	Non-Personal	NIL	N/A	N/A
Sarah Hartley	ULM EAG	Personal	Rosemont Pharmaceuticals	Salary	Yes

Sarah Hartley	ULM EAG	Non-Personal	NIL	N/A	N/A
Seamus Boland	MC1 EAG, Panel IGC	Personal	SGS International	Shares	Yes
Seamus Boland	MC1 EAG, Panel IGC	Personal	SGS International	Salary	Yes
Seamus Boland	MC1 EAG, Panel IGC	Personal	Janssen	Shares (immediate family member)	Yes
Seamus Boland	MC1 EAG, Panel IGC	Personal	Janssen	Salary (immediate family member)	Yes
Seamus Boland	MC1 EAG, Panel IGC	Non-Personal	NIL	N/A	N/A
Sean Jones	BPC, AIM EAG, WP AQbD	Personal	Peters & Peters Solicitors LLP	Consultancy	Yes

Sean Jones	BPC, AIM EAG, WP AQbD	Non- Personal	NIL	N/A	N/A
------------	-----------------------	---------------	-----	-----	-----

Sean Jones	BPC, AIM EAG, WP AQbD	Additional				Immediate family member is a QC analyst working for Catalent in Swindon. The site manufactures Zydis fast dissolving tablets.
------------	-----------------------	------------	--	--	--	---

Simeon Gill	BIO EAG	Personal	AstraZeneca	Salary and Shares	Yes
-------------	---------	----------	-------------	-------------------	-----

Simeon Gill	BIO EAG	Non- Personal	NIL	N/A	N/A
-------------	---------	---------------	-----	-----	-----

Simeon Gill	BIO EAG	Additional				AstraZeneca is a contract giver to contract
-------------	---------	------------	--	--	--	---

research and contract manufacturing organisations and partners with multiple other pharmaceutical organisations.

Alexion is a wholly owned division of AstraZeneca

Stephen Ellison	WP AQbD	Personal	LGC(Teddington) limited (Employer)	Salary and shares in LGC group	Yes
Stephen Ellison	WP AQbD	Non-Personal	NIL	N/A	N/A

Steven Nolan	MC1 EAG	Personal	United QP Consulting Ltd	Act as a consultancy to the pharmaceutical industry within Quality Assurance and as a releasing Qualified Person. The nature of products involved differs per client and contract.	Yes
Steven Nolan	MC1 EAG	Non-Personal	NIL	N/A	N/A
Stuart Paul-Adams	ULM EAG	Personal	NIL	N/A	N/A
Stuart Paul-Adams	ULM EAG	Non-Personal	NIL	N/A	N/A

Sushmita "Mimi" Roy	WP ATMP	Personal	NIL	N/A	N/A
Sushmita "Mimi" Roy	WP ATMP	Non-Personal	NIL	N/A	N/A
Tina Morris	WP AQbD	Personal	NIL	N/A	N/A
Tina Morris	WP AQbD	Non-Personal	NIL	N/A	N/A
Varada Bapat	MC1 EAG	Personal	RV Lifesciences LTD	Salary	Yes
Varada Bapat	MC1 EAG	Conferences/Scientific Meetings	NIL	N/A	N/A
Varada Bapat	MC1 EAG	Non-Personal	NIL	N/A	N/A
Vikas Jaitely	BPC, AIM EAG, Panel MIC	Personal	Merck Biopharma (Ares Trading SA- subsidiary	Salary (permanent employee)	Yes

I am responsible for Medical-Devices, Combination products

of Merck
Group
Germany)

and Digital
Health
products for
Merck
Healthcare.
This is
declared in
the first
section.
I proactively
declare any
interests for
items
before
every
meeting.

Vikas Jaitely	BPC, AIM EAG, Panel MIC	Non- Person al	NIL	N/A	N/A
Wayne Goddard	WP ATMP	Person al	North Tees and Hartlepool NHSFT	Full Time employee and currently Education & Training Lead for	Yes

				Pharmacy & QC	
Wayne Goddard	WP ATMP	Personal	Manchester University	Visiting Lecturer on PTQA MSc	Yes
Wayne Goddard	WP ATMP	Non- Personal	NIL	N/A	N/A
Wei Wang	WP ATMP	Personal	NIL	N/A	N/A
Wei Wang	WP ATMP	Non- Personal	NIL	N/A	N/A
Yvonne Perrie	BPC	Personal	NIL	N/A	N/A
Yvonne Perrie	BPC	Non- Personal	CURIA	Knowledge exchange research contracts from company to University of Strathclyde and joint	No

				PhD funding.	
Yvonne Perrie	BPC	Non-Personal	Imperial College London	Research Collaborator: VaxHub Grant to University of Strathclyde.	No
Yvonne Perrie	BPC	Non-Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in-kind research support (consumables).	No
Yvonne Perrie	BPC	Non-Personal	Avanti polar lipids/CRO DA	BBSRC Icase PhD studentship grant to University of	No

				Strathclyde	
Yvonne Perrie	BPC	Non-Personal	AstraZeneca	PhD studentships including licence.	No
Yvonne Perrie	BPC	Non-Personal	Defence Threat Reduction Agency DTRA (administered by DSTL)	Research Grant to University of Strathclyde	No
Yvonne Perrie	BPC	Non-Personal	Janssen Pharmaceutica	Research Grant to University of Strathclyde	No
Yvonne Perrie	BPC	Non-Personal	Target Healthcare	Knowledge Transfer Partnership research Grant to University of	No

Yvonne Perrie	BPC	Non-Personal	Takeda / Millenium Pharmaceuticals	Strathclyde Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	BPC	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	BPC	Non-Personal	Precision Nanomedicines Inc	Knowledge exchange	No

research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde to support project.

Yvonne Perrie	BPC	Non-Personal	NOF Corporation	Knowledge exchange research contracts from company to University of	No
---------------	-----	--------------	-----------------	---	----

Yvonne Perrie	BPC	Non- Person al	Micropore Technologi es Ltd	Strathclyd e Knowledg e exchange research contracts from company to University of Strathclyd e and joint PhD funding. Equipment loan to University of Strathclyd e. Innovate UK grant.	No
Yvonne Perrie	BPC	Non- Person al	pHion	Innovate UK grant to University of	No

				Strathclyde	
Yvonne Perrie	BPC	Non-Personal	ABITEC	Joint PhD funding	No
Yvonne Perrie	BPC	Non-Personal	Centre for process Innovation Ltd	Research Grant to University of Strathclyde	No
Yvonne Perrie	BPC	Non-Personal	Micropore ABITEC AstraZeneca Colorcon Croda	PhD CDT Training programme where I am Co-I. CMAC CEDAR	No
Yvonne Perrie	BPC	Non-Personal	Pfizer Sanofi Chiesi UCB Takeda Lilly Roche	Whilst not directly linked to my Nanomedicines theme in the PhD CDT programme, other	No

companies are linked to the grant.

Yvonne BPC
Perrie

Additional

I am Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). We are an internationally leading technological University and as such we work with many companies across the dept, faculty and University. We also work with Health care providers

including a wide range of NHS trusts and pharmacies through both research and education.

Yvonne BPC
Perrie Additional

I am Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). We are an internationally leading technological University and as such we work with many companies across the dept, faculty

and University. We also work with Health care providers including a wide range of NHS trusts and pharmacies through both research and education.

Zara Hannoun	WP ATMP	Personal	Oxford Biomedica	Share options	Yes
Zara Hannoun	WP ATMP	Personal	Zelluna Therapeutics	Salary	Yes
Zara Hannoun	WP ATMP	Non-Personal	NIL	N/A	N/A
Zena Smith	WP ATMP	Personal	Jazz Pharmaceuticals	Shares and Salary	

Zena Smith	WP ATMP	Non- Person al	NIL	N/A	N/A
---------------	------------	----------------------	-----	-----	-----

Contact information about these reports:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

© Crown copyright 2025

**Published by the Medicine and Healthcare products
Regulatory Agency**

ISBN 978-1-8384147-4-0

Guidance on reproducing and re-using MHRA Crown
copyright material can be found on our website at:

[http://www.nationalarchives.gov.uk/information-
management/re-using-public-sector-
information/copyright-and-re-use/crown-copyright/](http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/)